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Purpose: To evaluate the diagnostic performance of Coronary Computed 
Tomography Angiography (CCTA) in predicting Myocardial Perfusion 
Scintigraphy (MPS) perfusion defects in low likelihood patients with End 
Stage Renal Disease (ESRD) awaiting transplant. 
Materials and Methods: In total, 131 consecutive patients with ESRD 
awaiting transplant were prospectively enrolled in this study (86 men; 
54±9years). All patients underwent MPS as per standard of care and in 
addition non-enhanced CT for calcium scoring (CAC score) and Coronary 
Computed Tomography Angiography (CCTA). 
Results: The sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV) of CAC score in predicting MPS perfusion 
defects were 88%, 35%, 28% and 92%, respectively. 
The sensitivity, specificity, PPV and NPV of CCTA in predicting MPS perfusion 
defects at the patient level were 55%, 87%, 57% and 87%, respectively, and 
48%, 92%, 41% and 94% at the vessel level. The diagnostic performance of 
CCTA in predicting MPS perfusion defects improved when patients with CAC 
score higher than 1000 (15/70, 21%) were excluded from the analysis. In 
patients with positive CAC score up to 1000 sensitivity, specificity, PPV and 
NPV at the patient level were 60%, 93%, 75% and 86% respectively. These 
were 53%, 91%, 36% and 95%, respectively, at the vessel level. 
 
Conclusion: Non-enhanced CT for CAC score and CCTA can be considered 
useful diagnostic tools in the ESRD population, particularly in identifying 
patients without coronary artery disease. This approach however had 
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Chapter 1: Rationale and Aims of this Thesis 
Cardiovascular disease (CVD) is the major cause of morbidity and mortality 
in end stage renal disease (ESRD) patients . This includes ESRD patients who 
receive a renal transplant. Therefore, in the attempt to reduce cardiovascular 
events during the preoperative period and after transplantation, screening 
for coronary artery disease (CAD) in ESRD patients being considered for 
renal transplantation is common clinical practice (2).  
There are four main published guidelines for the preoperative cardiac 
evaluation of renal transplant candidates (3-6). Each of these guidelines, 
however, proposes slightly different criteria. The overall agreement amongst 
guidelines is poor and recommendations are at times inconsistent between 
guidelines (this will be discussed in detail in section 2.5.6). In Europe and the 
United States, myocardial perfusion scintigraphy (MPS) is the most widely 
used standard of care test to screen ESRD patients for CVD (7). However, it 
has been reported that the sensitivity of MPS in the detection of 
angiographically defined CAD was as low as 60% in dialysis patients (8). A 
potential explanation may be that concomitant conditions are often found in 
ESRD patients, such as left ventricular hypertrophy, or relative insensitivity 
to pharmacological stressors such as adenosine used for MPS imaging 
(discussed in section 2.6).  
The overarching hypothesis of this thesis is that non-invasive anatomical 
imaging of the coronary arteries, which does not require administration of a 
pharmacological stressor and is not substantially affected by left ventricular 
hypertrophy, may represent a valuable tool for cardiovascular screening in 
ESRD patients. 
The aims of this work were to compare coronary artery calcium (CAC) score 
(Aim 1) and coronary computed tomography angiography (CCTA) (Aim 2) 
with MPS for the diagnosis of CAD in patients with ESRD. We have evaluated 





Chapter 2: Renal and Cardiovascular Disease 
2.1 Definitions of End Stage Renal Disease (ESRD) and Chronic Kidney 
Disease (CKD) 
End Stage Renal Disease (ESRD) is characterized by irreversible or nearly 
complete loss of renal function and represents the final stage of chronic 
kidney disease (CKD). CKD is a progressive loss of renal function due in 75% 
of cases to diabetes, hypertension or glomerulonephritis. CKD occurs either 
when there is a structural or functional abnormality of the kidney for at least 
3 months with or without decrease of the estimated glomerular filtration rate 
(eGFR), or when the eGFR decreases to <60ml/min/1.73 m2 (National Kidney 
Foundation, https://www.kidney.org/)(9). 
eGFR is an estimate of the glomerular filtration rate – a measure of the 
excretory function of the kidney.  In order to calculate the eGFR an estimating 
equation is required. The Modification of Diet in Renal Disease (MDRD) Study 
equation is one of the most widely used equations for estimating GFR in 
patients age 18 and over.   This formula estimates GFR adjusted for serum 
creatinine, age, ethnicity, and gender and because the results are normalized to 
1.73 m
2
 body surface area, it does not require weight or height variables (10).  
Proteinuria occurs as a result of the damage to the glomeruli and indicates 
presence of serum proteins in the urine. Proteins in the blood, like albumin, 
are too large to pass through the glomeruli into the urine. When the 
glomeruli are damaged, proteins of various sizes pass through them and are 
excreted in the urine. 
It is widely accepted that proteinuria (and even more albuminuria) is a 
predictor of cardiovascular disease including ischaemic heart disease, stroke 
and hypertension in the general population (11). According to the Steno 
hypothesis (12) urinary protein excretion reflects localised subclinical renal 
disease and also a more generalised vascular endothelial dysfunction which 
is part of the atherosclerotic process (section 2.2)  
CKD has five stages: 
- Stage 1:  GFR ≥ 90 ml/min/1.73 m2 
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- Stage 2:  GFR 60 – 89 ml/min/1.73 m2 
- Stage 3:  GFR 30 – 59 ml/min/1.73 m2 
- Stage 4:  GFR 15 – 29 ml/min/1.73 m2 
- Stage 5:  GFR < 15 ml/min/1.73 m2 or End Stage Renal Disease (ESRD) 
 
For the definition of CKD in stage 1 and 2, structural or urinary abnormalities 
are also required. For patients in Stage 5 CKD or ESRD, renal replacement 
therapy is required in the form of either renal transplant or dialysis.  
 
 
2.2. ESRD and Cardiovascular disease 
The primary cause of mortality and morbidity in the ESRD population is CVD. 
The most common causes of cardiovascular death in ESRD are CAD, heart 
failure and arrhythmia (13). Despite an increase in life expectancy of ESRD 
patients related to the introduction of dialysis treatment, the mortality rates 
are still very high in these patients (14). An elevated cardiac mortality also 
persists after renal transplantation, particularly in the first year when the 
graft is still functional (15).  
A variety of patient-related and dialysis-related factors have been shown to 
accelerate the atherosclerosis process in this population (16). The prevalence 
of atherosclerotic CAD in the ESRD population is thought to be greater than 
in age-matched controls and higher than it can be explained based on the 
conventional Framingham risk factors alone (1, 16). 
There is substantial evidence of a negative correlation between glomerular 
filtration and cardiovascular disease. As the glomerular filtration decreases, 
the incidence of cardiovascular disease (CVD) increases independently from 
other risk factors (17, 18). 
Furthermore, there is a strong association between the entity of 
microalbuminuria and the occurrence of cardiovascular events (19), perhaps 
through the association of microalbuminuria with endothelial dysfunction, 
which is one of the early stages of the atherosclerotic process in the vessel 
walls. In particular, endothelial dysfunction could directly influence 
albuminuria by increasing glomerular pressure and glomerular membrane 
permeability. Endothelial dysfunction can also indirectly influence 
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permeability by  inflammatory mechanisms. As a result of impaired renal 
function, there is accumulation of uraemic toxins which, together with 
traditional cardiovascular risk factors (hypertension, diabetes, cigarette 
smoking and dyslipidaemia), play an important role in the induction of 
endothelial dysfunction (18). Renal impairment is typically associated with 
an increase of inflammatory biomarkers and chronic inflammation plays an 
important role in the atherosclerosis process. The atheroma is an active 
cellular lesion and many of the cells contained in the lesion facilitate 
inflammation, or result from inflammation (20). Inflammation is also one of 
the most important determinants of plaque “vulnerability”, i.e. its 
susceptibility to rupture or erode as well as its thrombogenic potential , (12, 
21). The plasma accumulation of uraemic toxins (partially removed by 
dialysis) together with dialysis-related factors results in an increase in the 
concentration plasma pro-inflammatory cytokines as well as other 
inflammatory biomarkers (22, 23) (Figure 1). 
 
 
Figure 1: Mechanisms by which traditional cardiovascular risk factors combined 
with uraemia-related and dialysis-related risk factors induce a systemic 





Renal impairment and microalbuminuria are associated with a range of lipid 
abnormalities (24). In this population the lipoprotein metabolism is 
compromised and this may result, especially in the most advanced stages, in 
the development of severe dyslipidaemia (25). In particular, there is a 
decrease of the HDL and HDL2 cholesterol known to be protective against 
CVD and there is an increase of triglycerides and VLDL cholesterol. 
Derangements of the lipid profiles can be described as below: 
- Hypertriglyceridaemia: hypertriglyceridaemia [due to accumulation of 
VLDL and remnant lipoproteins such as intermediate-density lipoprotein 
(IDL)] is one of the most common abnormalities in CKD patients (26, 27) 
showing the highest values in dialysis patients (25). Delayed catabolism is 
the predominant mechanism responsible for increased concentration of 
triglycerideride lipoproteins in this population (28). The reason for 
diminished catabolic rate is the reduction of the lipoprotein lipase activity 
which is likely to be caused by a down-regulation of the enzyme’s gene (29) 
and the presence of lipase inhibitors (30). Furthermore patients with CKD 
suffer from insulin resistance and this will promote hepatic VLDL 
production(31-33). 
 
- Low density lipoprotein (LDL): Plasma total cholesterol in CKD population 
varies and it is usually normal or reduced; only occasionally this can be 
elevated in ESRD patients (25). The degree of proteinuria is a significant 
factor that influences the levels of plasma cholesterol-rich lipoproteins (25). 
The absence of heavy proteinuria in CKD does not significantly affect gene 
expressions of the rate-limiting enzyme for cholesterol biosynthesis (HMG-
CoA reductase) or the rate-limiting enzyme for cholesterol catabolism and 
conversion to bile acids (7a-hydroxylase) (34). Hepatic LDL receptors 
mediate the cholesterol uptake and are not altered in absence of proteinuria 
(34). 
In contrast, patients with nephrotic range proteinuria exhibit an acquired 
LDL-receptor deficiency (35). Studies in animals with experimental 
nephrosis revealed an upregulation of HMG-CoA reductase (36) as well as a 
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relative reduction of cholesterol 7a-hydroxylase (37). All the aforementioned 
mechanisms in concert may result in the increase of LDL blood levels in 
patients with proteinuria. 
 
- High density lipoprotein (HDL): HDL proteins play a key role in the 
homeostasis of cholesterol and protection against atherosclerosis. They are 
responsible for the reverse cholesterol transport (transport of excess 
cholesterol from the arterial wall to the liver for excretion) and, moreover, 
inhibit inflammation and platelet adhesion(38). Patients with CKD have, 
generally, reduced plasma HDL cholesterol levels compared to individuals 
with normal renal function (39-41) and multiple mechanisms are involved: 
1) Decreased levels of apolipoproteins AI and AII (the main protein 
constituents of HDL) (41). 
2) Diminished activity of lecithin-cholesterol acyltransferase (LCAT) (the 
enzyme responsible for the esterification of free cholesterol in HDL particles) 
(29, 42). 
3) Increased activity of cholesteryl ester transfer protein (whose role is the 
transfer of cholesterol esters from HDL to triglyceride-rich lipoproteins thus 
reducing the serum concentrations of HDL-cholesterol) (43). 
4) HDL particles from individuals with CKD have less effective antioxidative 
and anti-inflammatory function (44, 45). 
 5) The type of membrane and dialysate used in haemodialysis procedure 
may also influence the HDL-cholesterol levels (46, 47), in particular a low-
flux instead of high flux membranes and the use of acetate dialysate are 
associated with a decrease of the HDL-cholesterol values (48, 49). 
 
Carbohydrate metabolism disorders are also common in ESRD patients. 
Diabetes mellitus is present in a large group of patients on dialysis as one of 
the most common cause of ESRD. However, non-diabetic patients can also 
develop glucose intolerance (50), probably due to peripheral insulin 
resistance mainly resulting from uraemic toxins. Insulin resistance may 
contribute to the high cardiovascular morbidity and mortality in this 
population (51, 52). 
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Hypertension is very common in the ESRD population and its prevalence can 
range from 60% to 100% depending on the cause and severity of CKD (13). 
It has been reported that high systolic blood pressure (>180 mmHg) as well 
as low systolic blood pressure (<100 mmHg) are associated with increased 
mortality in this population (53). CKD and high blood pressure are related in 
two ways: 
1) High blood pressure is one of the leading causes of CKD and it still remains 
the second most common cause of ESRD after diabetic nephropathy (54). 
High blood pressure cannot only play a solitary role in the development of 
CKD but it has also been shown that coexistent hypertension (even mild-to-
moderate blood pressure elevations) has an important role in the 
progression of most chronic kidney diseases (55, 56), including diabetic 
nephropathy. 
2) High blood pressure can also represent a complication of CKD and there 
are several causes for this(57): 
- Impaired sodium excretion resulting in expansion of the extracellular fluid 
compartment (57). 
- Direct vasoconstriction effect due to activation of the renin-angiotensin 
system, sympathetic activation and increased production of endothelin (57). 
- Loss of  vasoconstriction effect due to nitric oxide and kinins (57). 
- Imbalance between vasodilator and vasoconstrictor prostaglandins (58). 
 
CKD patients, and nearly all those with ESRD who are on dialysis, are at risk 
of developing anaemia. As haemoglobin concentrations decrease to less than 
11 g/dL there is a corresponding increase in the rate of hospitalisation and 
mortality in patients with CKD (59). The interaction between anaemia and 
renal failure is complex and multifactorial (60), the most common causes 
include: 
1) Erythropoietin (EPO) deficiency: approximately 90% of the EPO is 
produced by the kidneys under hypoxic stimulation resulting into 
erythropoiesis stimulation (61). Damaged kidneys are unable to produce 
adequate EPO as result of hypoxia (61). 
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2) Systemic inflammation: inflammation together with microvascular disease 
(especially in diabetes patients) stimulates the production of inflammatory 
mediators (such as interleukins and tissue necrosis factor) and these can 
blunt the effect of the EPO on the bone marrow (62). 
Other causes are shortened red cell life span and haemolysis (secondary to 
uraemic toxins accumulation), vitamin deficiencies, iron deficiency, and 
hyperuricaemia (leading to bone marrow suppression) (63). 
  
The clinical consequences of anaemia depend on the severity of the oxygen 
reduction and the adaptive response to this change (64). There is an initial 
adaptive increase of the cardiac output that can become maladaptive as a 
result of stimulation of the left ventricular (LV) growth leading to left 
ventricular hypertrophy (LVH) and LV dilatation (65). Another important 
aspect in which anaemia can play a role (together with reduced vasodilator, 
microvascular disease and supply and demand mismatch due to LVH), is the 
occurrence of angina without CAD, seen in about 70% of patients with ESRD 
(8, 66).  
  
It is worth noting that the presence of chest pain does not correlate with the 
presence and extent of CAD (7). It has been shown that the presentation of 
acute and chronic ischaemia can differ quite dramatically between ESRD and 
non-ESRD populations, which includes patients hospitalised with acute 
myocardial infarction (AMI) (67). In this regard, among ESRD patients on 
dialysis who are diagnosed with an AMI only 44.4% presented with acute 
chest pain as a symptom, compared to 68.3% in the non-ESRD population 
(p<0.0001) (67). 
 
ESRD patients with chronic, stable CAD documented angiographically tend to 
have no symptoms too (68). In fact, in three studies (69-71), dialysis patients 
with angiographically documented CAD had no symptoms in 75%, 74% and 
67% of the cases, respectively. The lack of symptoms is mainly attributed to 
diabetes and uraemic neuropathy (68). Moreover, ESRD patients generally 
have a sedentary lifestyle due to reduced exercise capacity from muscle 
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fatigue, anaemia and generalised feeling of illness after dialysis. These 
factors, secondary to rapid fluid and electrolyte shifts related to the dialysis 
treatment, contribute greatly to the lack of symptoms.  
 
 
2.3. Uraemic Cardiomyopathy 
There are different and confusing terms to define this condition. In practice, 
uraemic cardiomyopathy is the result of the influence of the pathological 
renal function on the myocardium that ultimately leads to LVH. LVH is 
defined as an increase in the mass of the LV, which can be secondary to an 
increase in wall thickness; normal ranges for septal wall thickness are 0.6-1.0 
cm in men and 0.6-0.9 in women (72). LVH in ESRD is the result of pressure 
and volume overload as well as the uraemic state. LVH is indeed the first and 
most common cardiac adaptation in CKD and it is present in up to 75% of this 
population (73-75). 
LVH can be present also in subjects with modest CKD, and importantly it is an 
independent predictor of survival in these patients (76-78). 
LVH is the adaptive response to a variety of physiological and pathological 
stresses resulting in the enlargement of myocytes. The consequence of this is 
an initial normalisation of the wall tension in order to maintain the systolic 
function (15). In the very early stage, LVH is a beneficial adaptive response. 
Evidence exists, however, that hypertrophied hearts are more prone to injury 
and ventricular dysfunction (79), as LVH may initiate a cascade of 
detrimental maladaptative changes. In advanced stages the LV can be dilated 
with systolic and diastolic dysfunction (80, 81), ultimately resulting in heart 
failure (82). 
 
It has been shown that capillary growth in the uraemic heart does not 
increase with myocyte hypertrophy (83, 84) and this results in a greater 
diffusion distance between the capillary and the centre of the myocyte. This 




Uraemia increases the activation and proliferation of cardiac interstitial 
fibroblasts (86-88) with the deposition of collagen fibres between capillaries 
and myocytes (myocardial fibrosis). Fibrosis is another common change that 
occurs during CKD (89), as confirmed in both experimental models (88, 90, 
91) and post-mortem studies (92). Fibrosis plays a role in the progression of 
maladaptative LVH including reduced compliance of the heart (93) and also 
contributes together with the reduced capillary density, to oxygen starvation 
that increases the susceptibility to ischaemia (85, 89). Another detrimental 
consequence of fibrosis, together with electrolyte alterations seen in CKD, is 
the increased risk of arrhythmia (94). 
 
2.4 Vascular Calcification in Patients with CKD 
The three most common CVD presentations in CKD population are CAD, LVH 
and peripheral vascular disease. The main lesions responsible for the clinical 
manifestations in the coronary tree and peripheral vascular disease are 
atherosclerosis of the intima and vascular calcifications of the media (95). 
Medial vascular calcifications can involve the whole vascular system and they 
are particularly common in CKD (95). Normally mesenchymal stem cells can 
differentiate to adipocytes, osteoblasts, chondrocytes and vascular smooth 
muscle cells (VSMC). In the presence of CKD, aging, diabetes, inflammation 
and other toxins, the VSMC can differentiate to osteo/chondrocytic-like cells 
that can become calcified in a process similar to bone formation and results 
in vascular calcifications (96). This process is accelerated in the context of 
high calcium and phosphorus levels and abnormal bone remodelling. 
 
Metabolic bone disease is a frequent complication in CKD and alterations in 
the control mechanisms for calcium and phosphorus homeostasis can occur 
in early stages of CKD and progress as kidney function decreases (97). There 
are two main abnormalities in bone metabolism: 
1) High turnover: this is the result of hyperparathyroidism. It is well known 
that even in the early stages of CKD there is some degree of hyperplasia of 
the parathyroid glands and high levels of PTH (98, 99). Numerous factors can 
lead to this including the retention of phosphorus, the decrease in the levels 
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of calcitriol, increase PTH secretion, increase parathyroid growth, skeletal 
resistance to the actions of PTH, and hypocalcaemia. All of these factors are 
closely interrelated and one or more can be predominant in a particular stage 
of CKD (97).  
2) Adynamic bone: also known as low-turnover bone disease, is more 
common in dialysis patients. It is characterised by a slow rate of bone 
formation - its pathogenesis is not well defined, but it seems multifactorial 
(100). 
This condition may result from a hypoparathyroid state that is due to the use 
of high-dialysate calcium concentrations, administration of high calcium 
loads from calcium-containing phosphate binders or and the use of vitamin D 
sterols (97). 
High turnover and adynamic bone are different skeletal abnormalities and 
generate a wide spectrum of skeletal changes that can result in a variety of 
mixed patterns known as “mixed renal osteodystrophy” with results of the 
effects of hyperparathyroidism together with mineralisation defects (97).  
Other factors that may lead to decreased bone formation are age, increased 
peptides in the circulation (such as osteoprotegerin and N-terminally 
truncated PTH fragments), uraemic toxins, reduced expression of PTH 
receptors, alterations in concentrations of growth factors and cytokines that 
affect bone turnover, acidosis, corticosteroid therapy–induced osteoporosis, 
or malnutrition (97). 
Both high and low bone turnover play a role in the formation of the vascular 
calcification either by not allowing calcium and phosphorous into the bone 
(low turnover) or by reabsorbing the calcium out of the bone (high 
turnover)(96).  
Lack of inhibitors/regulators of calcifications can also play a role in the 




Figure 2: Pathogenesis of vascular calcifications. Adapted from (96). Mesenchymal stem 
cells in the setting of CKD, diabetes, aging, inflammation and multiple other toxins can 
differentiate into osteo/chondrocytic-luke cells (due to upregulation of transcription 
factors like RUNX-2 and MSX2), calcifie and lay down non-collagenous proteins as well as 
collagen in the intima and media and incorporate phosphorus and calcium into matrix 
vesicles to trigger mineralisation. The overall positive balance of calcium and phosphorus 
supports the generation of matrix vesicles and the cellular transformation. The extremes 
of bone turnover in CKD will also increase the availability of phosphorous and calcium. In 
the end the strength of the army of inhibitors (I) will influence whether an artery will 
calcify or not. Inhibitors are in the arteries (PPI=pyrophosphate, 
OP=osteopontine,MGP=matrix Gla protein) or they stand in the circulation (fetuin-A) 
 
 
Several circulating biomarkers are involved in the regulation of the 
calcification process, such as the fibroblast growth factor 23 (FGF23), 
osteoprotegerin (OPG), RANK ligand, osteopontin (OPN), Klotho protein and 
bone morphogenetic protein-7 (BMP-7) (101). 
Calcifications of the intimal and medial layers of the vessel wall are 
associated with cardiovascular symptoms, morbidity and mortality (96). In 
the CKD population, in the medial layer of the arterial wall calcifications 
develop mainly as a result of diabetes and mineral metabolism abnormalities, 
such as uraemia (96, 102). In the intimal layer, calcifications seem associated 
with a mix of atherosclerotic risk factors and renal impairment, showing an 
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association with kidney function abnormalities, smoking, diabetes, alteration 
of calcium-phosphorus metabolism and aging (102). 
Nakamura et al (102) performed autopsy on 117 subjects with significant 
CAD and a wide range of renal function (ranging from normal to stage 5 of 
CKD). Most of adult patients with CKD suffer from both intimal and medial 
calcifications (102), whereas subjects with normal renal function only 
presented intimal calcifications. 
Medial calcifications contribute to vascular stiffness, which increases the 
pulse-wave velocity and decreases diastolic blood pressure and increases 
systolic blood pressure (103). Medial calcifications contribute to the overall 
cardiovascular mortality in the ESRD population but they are not a marker of 
atherosclerosis (104). 
Intimal calcifications, on the other hand, are more closely linked to 
atherosclerosis (104) and appear to be associated with cardiovascular events 
(103), in fact both ESRD and non-ESRD populations with predominantly 
intimal calcifications have a higher risk of mortality (104, 105). 
 
ESRD worsens all the risk factors that contribute to the formation of both 
types of coronary artery calcification. Coronary calcification progresses 
during dialysis, with systemic inflammation acting as an important 
independent risk factor favouring progression (106, 107). 
However, kidney transplantation can slow down - but is unlikely to stop – the 
progression of coronary artery calcification compared to the pattern 
observed in the dialysis population, possibly because of a regression in the 
uraemic milieu obtained after transplantation (95). 
 
The progression of coronary calcifications after renal transplantation is 
strongly related to the baseline CAC score. The higher the baseline CAC score 
the more progression there is (95, 108). There is a variable association of 
other risk factors, particularly Framingham risk factors (smoking, blood 
pressure and dyslipidaemia) that can affect this progression (95). 
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The role of diabetes as a predictor for CAC is well known (109, 110) but its 
independent association with both kinds of calcification progression is still 
unclear (95). 
 
The role of immunosuppressive therapy in slowing down the progression of 
vascular calcifications has been reported, but its mechanism is not 
completely understood (109, 111, 112). 
 
Some patients, despite the presence of multiple risk factors, do not develop 
CAC even in long-term dialysis (113, 114). There is no clear explanation for 
this but the vast majority of authors who have examined this aspect 
hypothesised that these patients have high levels of protective factors either 
in the blood vessel or in the circulation or both (96). For example, the Fetuin-
A serum level is responsible for 50% of the calcification inhibitory capacity 
(95). Levels of this inhibitor go down during inflammation, and low levels of 
Fetuin-A in dialysis are associated with vascular as well as valvular 
calcification and death (115). 
In a large group of > 300 dialysis patients it was found that low concentration 
of serum fetuin-A levels was associated with significantly increased all-cause 
and cardiovascular mortality (116). The variability in the levels of fetuin-A 
has a possible genetic explanation, in fact Stenvinkel et al (117) discovered 
that a specific fetuin-A gene polymorphism (Thr256Ser) predicted 
particularly low fetuin-A levels and this was associated with an adverse 
prognosis compared to patients carrying alternative gene polymorphisms. 
 
Calcifications can be detected through imaging techniques such as plain 
radiography and computed tomography (CT), the latter being widely used in 
clinical practice for the detection of CAC (CAC score). The CAC score is a 
marker of the amount of coronary calcification, but due to limitations in 
spatial resolution, cannot differentiate medial from intimal calcifications. 
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2.5. Guidelines for Cardiovascular Screening in ESRD 
Cardiovascular screening is generally recommended in patients with ESRD 
under consideration for renal transplantation (66). Clinical 
recommendations are available provided by four main guidance documents 
(3-6, 118) The four main guidelines are shown in figure 3a and 3b.  
 
   
   
Figure 3a adapted from (119). KDOQI : Kidney Disease Outcomes Quality Initiative. ASCVD: 




Figure 3b adapted from (119). ASCVD: arteriosclerotic cardiovascular disease; ACC/AHA: 
College of Cardiology/American Heart Association; MET: Metabolic Equivalent. 
 
 
2.5.1 Kidney Disease Outcomes Quality Initiative (KDOQI)  
According to the KDOQI guidance (3), non invasive stress testing should be 
performed. This may include exercise treadmill testing, if patients are able to 
exercise, or a pharmacological stress test, e.g. dobutamine stress 
echocardiographycardiography or adenosine/dipyridamole stress 
myocardial perfusion imaging, based on availability and expertise. 
Non invasive stress testing is recommended for: 
 All patients with diabetes (to be repeated every 12 months) 
 All patients with prior CAD: 
a) If not revascularised, to be repeated every 12 months 
b) If revascularised with prior percutaneous coronary intervention (PCI), 
to be repeated every 12 months 
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c) If revascularised with prior coronary artery bypass grafting (CABG), 
repeat after first 3 years and then every 12 months 
 To be repeated every 24 months in high risk non-diabetic patients 
defined as: 
a)  ≥ 2 traditional risk factors 
b) Known history of CAD 
c) LV Ejection Fraction ≤40% 
d) Peripheral vascular disease 
 
 
2.5.2 Evaluation of Renal Transplant Candidates by the American Society of 
Transplantation (AST)  
According to the Evaluation of Renal Transplant Candidates, published by the 
American Society of Transplantation (AST) (66), non-invasive stress testing 
is recommended in patients with:  
 Diabetes mellitus 
 Prior history of CVD 
 ≥ 2 of the following risk factors: 
a) Family history of CAD 
b) LVH 





2.5.3 Report of the Lisbon Conference on the Care of the Kidney Transplant 
Recipient (Lisbon) 
According to the Lisbon guidance (5), non-invasive and/or invasive test 
should be considered in patients with the following conditions: 
 Diabetes mellitus 
 Prior history of CVD 
 Multiple risk factors (does not specify the number of risk factors to justify 
a test): 
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a) > 1 year of dialysis 
b) LVH 





2.5.4 American College of Cardiology/American Heart Association 2007 
Guidelines on Peri-operative Cardiovascular Evaluation and Care for Non-
cardiac Surgery (ACC/AHA)  
According to the ACC/AHA 2007 guidance (6), the decision to proceed with 
screening should be based on the symptoms and the functional capacity of 
the patient, known as Metabolic Equivalent (MET). The MET is a largely used 
physiological concept that expresses the energy cost of physical activities as a 
multiple of the resting metabolic rate (Table 1) (120): 
 No test is recommended if the functional status is ≥ 4 METS 
 If the functional status is ≤ 4 METS or unknown a non-invasive stress test 
is recommended, based on the following risk factors: 
a) Known ischaemic heart disease 
b) Compensated or prior heart failure 
c) Diabetes mellitus 
d) Renal failure 
e) Cerebrovascular disease 
 
Recommendations for testing are stronger if there are ≥ 3 risk factors, but 

















Table 1: Metabolic Equivalent (MET) for different activities. Adapted from 
(121). 
 
Physical activity  MET 
Light intensity activities < 3 
Sleeping 0.9 
Watching television 1.0 
Writing, desk work, typing 1.8 
Walking, 1.7 mph (2.7 km/h), level ground, strolling, very slow 2.3 
Walking, 2.5 mph (4 km/h) 2.9 
Moderate intensity activities 3 to 6 
Bicycling, stationary, 50 watts, very light effort 3.0 
Walking 3.0 mph (4.8 km/h) 3.3 
Calisthenics, home exercise, light or moderate effort, general 3.5 
Walking 3.4 mph (5.5 km/h) 3.6 
Bicycling, <10 mph (16 km/h), leisure, to work or for pleasure 4.0 
Bicycling, stationary, 100 watts, light effort 5.5 
Sexual activity 5.8 
Vigorous intensity activities > 6 
Jogging, general 7.0 
Calisthenics (e.g. pushups, situps, pullups, jumping jacks), heavy, 
vigorous effort 
8.0 
Running jogging, in place 8.0 





2.5.5 Variability in Guidelines for Cardiovascular Screening before Renal 
Transplant and Ethical Debate 
In a study published in 2011 by Friedman et al (119), the authors applied 
each guideline to a cohort of renal transplant candidate in order to identify 
variations between them. Data showed a large difference in the rate of 
cardiac evaluation form 100% (KDOQI) to 20% (ACC/AHA). AST and Lisbon 
respectively showed cardiac evaluation rates of 92% and 68%. These results 
showed that some guidelines (KDOQI, AST and Lisbon) had a more 
aggressive approach compared to a more conservative approach promoted 
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by the ACC/AHA, the latter recommending cardiac testing only in the 
presence of either symptoms or poor functional status. 
In light of the operative and long term mortality, as well as donated organs 
being a precious and limited resource, there is an ethical debate on the 
impact and utility of cardiovascular screening in patients awaiting a 
transplant (7, 122-124). The rationale in favour of screening is that CAD is a 
major cause of premature CVD mortality. By identifying and treating early 
CAD there may be better chances that the outcomes of these patients may 
improve. However, there is at present little evidence to support 
cardioprotective therapy in this group. Uremic cardiomyopathy may be a 
stronger factor than CAD affecting CVD mortality in ESRD patients  (125).  
 
Although screening will identify patients with significant CAD, intervention is 
seldom performed (3% of cases) (7). The survival rate of patients who 
underwent intervention was reported as not significantly better than 
patients who were not treated, hence at present the benefits of intervention 
are not clear (122).  
Another potential practical problem of screening may be its impact on the 
delay of the transplantation. Ideally, a screening process should be rapid. 
Patients on dialysis awaiting for transplant have a high mortality rate. Delays 
in wait listing may increase mortality even further. Future randomised 
controlled trials will be needed to clarify the impact of CAD and uremic 
cardiomyopathy on survival and cardiovascular event rates in asymptomic 
ESRD patients. 
  
2.6 Invasive Coronary Angiography and Identification of Patients Requiring 
Coronary Revascularisation 
In a study including 287 American centres, myocardial perfusion 
scintigraphy (MPS) was found to be the commonest first-line screening 
strategy in ESRD patients, while approximately 15% of centres used invasive 
coronary angiography as primary method (126). 
Coronary angiography, the ’gold standard’ for the assessment of CAD, is 
invasive and exposes patients to the risk of complications. Unpublished 
 29 
statistics from the London Chest Hospital (2010-2012) showed that 
approximately 10% of ESRD patients undergoing angiography received 
coronary revascularisation. This figure is in keeping with the performance of 
the available guidelines whose positive predictive value in the identification 
of patients requiring coronary revascularisation is reported between 5.9% 
and 10% (119). Coronary angiography is a well established technique but it 
is riskier than non-invasive tests. Complications include arrhythmias, the risk 
of developing atrial fibrillation, thromboembolic events (which may result in 
stroke or myocardial infarction), haemorrhage at the site of vascular 
puncture, arterial thrombosis, and renal damage secondary to the use of 
intrarterial iodinated contrast. Importantly, coronary angiography in ESRD 
patients is riskier than in non-ESRD patients (crude 4-year survival: hazard 
ratio 4). Therefore, the current consensus us that the use of invasive 
angiography for merely diagnostic purpose should be minimised where 
possible (127). 
 
2.7 Myocardial Perfusion Scintigraphy (MPS) in ESRD 
MPS is a well-established, widely used technique in the general and CKD 
population. MPS enables the evaluation of cardiac perfusion and function at 
rest and during dynamic exercise or more commonly during pharmacologic 
stress. MPS requires the administration of a radioisotope (thallium-201 or 
99mTc-Sestamibi) and a dedicated gamma-camera which is able to detect the 
gamma photons. The fundamental principle of the technique is the flow-
dependent and/or metabolism-dependent selective uptake of a radioisotope 
tracer by functional myocardial tissue. Under stress condition, the 
abnormally perfused myocardium receives less blood flow than normally 
perfused myocardium. Stress images show the distribution of the 
radioisotope, and therefore the relative blood flow to the different regions of 
the myocardium. When comparing stress images with rest images it is 
possible to identify perfusion defects. These can be secondary to CAD or a 
consequence of uraemic cardiomyopathy. MPS does not require the 
administration of iodinated contrast. This is an advantage for CKD patients in 
pre-dialysis. Although the sensitivity of MPS for the detection of CAD 
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compared to invasive angiography was reported as >90% in non-ESRD 
patients, the majority of studies carried out in patients with ESRD reported 
lower sensitivity values in the range of 29-86% (2, 128, 129). The specificity 
of MPS in ESRD has been reported in the range of 72-76% (2, 128, 129). 
Several factors may account for this. ESRD patients have high levels of basal 
adenosine and high resting coronary flow. Pharmacologic MPS generally uses 
adenosine or dipyridamole as vasodilator to induce stress by challenging the 
coronary flow reserve. Coronary flow reserve can be defined as the ability of 
the coronary flow to increase above the normal resting values when 
metabolic requirements demand it, and this is achieved mainly by dilatation 
and recruitment of small intramural coronary arteries (130). The higher 
resting blood flow may blunt the flow reserve, potentially compromising the 
sensitivity of MPS by decreasing the heterogeneity of radioisotope uptake, 
which is the basis of detection of CAD by this modality (129). Moreover, MPS 
can yield positive findings in case of LVH even when CAD is absent (131, 
132). Although MPS perfusion defects are useful in identifying patients with 
an increased risk of future cardiovascular events (133), it is not clear 
whether the increased risk is due to CAD or other expressions of cardiac 
disease e.g., uraemic cardiomyopathy characterised by decreased myocardial 
cellular components, more fibrosis and LVH.  
 
Recently, it has been reported (134) that MPS can perform well in a limited 
subgroup of ESRD patients, i.e. those who do not have cardiac symptoms and 
do not present any factor that can impact on the coronary flow, such as 
anaemia, family history of CAD or known CVD, hepatitis C virus infection, 
obesity (body mass index ≥30 kg/m2), autoimmune disease, 
hyperphosphataemia, abnormal calcium-phosphorus product and 
echocardiographycardiographically-established LVH. With characteristics 
such as LVH or some of the cardiovascular risk factors being rather common 
features (given the suboptimal performance of MPS in the majority of ESRD 
patients who present at least one or a few of these features) an alternative 





2.8 Role of Dobutamine Stress Echocardiography and Cardiac Magnetic 
Resonance in ESRD 
Dobutamine or dipyridamole stress echocardiography (DSE) detects 
inducible myocardial ischemia by detecting wall motion abnormalities under 
stress, which reflect underlying significant CAD. A large metanalysis (135) 
has recently shown that the prognostic value of an abnormal DSE is similar to 
that of coronary angiography in predicting outcomes of cardiovascular 
mortality and major acute cardiovascular events (MACE). The authors 
however found a moderate sensitivity of 80% in detecting inducible 
myocardial ischemia in patients awaiting transplant (135). There are several 
possible explanation for this. A reduced response to the stressor or presence 
of LVH can make the detection of wall motion abnormalities more difficult in 
ESRD patients (136). On the other hand, a negative stress echocardiography 
remains associated with low incidence of MACE (137). 
 
Cardiac magnetic resonance (CMR) with gadolinium is contraindicated when 
the eGFR is below 30 ml/min/1.75 m2 due to the reported small risk of 
nephrogenic systemic fibrosis. Gadolinium free techniques, however, are safe 
and could play a role in this population. In the general population, 
dobutamine CMR has excellent diagnostic accuracy for detection of 
significant CAD (138) as well as an excellent prognostic utility in patients 
with known or suspected CAD (139) . Very little data however are available 
in the ESRD population. 
 
It has been shown recently that CMR can play a role in LV myocardial tissue 
characterization using the native T1 mapping technique (140). This magnetic 
resonance imaging technique is sensitive to the difference in the native 
longitudinal relaxation time (T1) of tissues, therefore it can be applied 
without the injection of gadolinium. Tissue changes characterized by an 
expansion of the myocardial extracellular volume compartment will have an 
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abnormal T1. These changes can be detected and quantified. It was found 
that hemodialysis patients may have prolonged T1 relaxation times, 
which,correlated with increased LVH and may suggest increased diffuse 
myocardial fibrosis.     
Diffuse myocardial fibrosis detected with imaging could be used as a 
prognostic marker and to target specific treatments. Deep tissue phenotyping 
with this non-invasive approach could reveal useful to opmitise the timing of 
renal transplantation to maximize cardiovascular outcomes. 
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Chapter 3: Coronary Artery Calcium (CAC) Score 
 
3.1     Technical Aspects  
The detection of coronary artery calcifications with electron beam computed 
tomography (EBCT) and computed tomography (CT) provides a fast method 
for the assessment of coronary artery calcification with no need of contrast 
media injection (141). 
At present, EBCT scanners are no longer in production having been 
superseded by CT scanners. 
CT can detect calcifications in the vessel walls because of their X-ray 
attenuation which is higher than those of the myocardium and epicardial 
tissue, and similar to that of bone (142). In the heart, motion-free images are 
essential in order to have accurate quantification of calcification in the 
coronary arteries. For this reason, electrocardiographically (ECG)-
synchronised protocols are used for image acquisition. Generally, 3mm-thick 
images are reconstructed over the heart range, with a slice interval of 1.5mm. 
The effective radiation dose associated a CAC score scan varies greatly from 
0.8 to 10.5 mSv (with a mean of 2.3 mSv) across CT scanners of different 
generations, primarily depending on the use of different acquisition 
protocols. With current technology, CAC score scans are associated with 
radiation exposures of the order of 1-3mSv. CAC score scans can be acquired 
using either retrospectively-ECG gated protocols (as in older generation 
scanners) which are associated with higher radiation exposures, or 
prospectively-ECG triggered protocols (new generation scanners), generally 
associated with lower radiation exposures (143). Briefly, in prospectively 
ECG-triggered protocols (‘step-and-shoot’ scanning) the table moves in a 
step-wise fashion and X-rays are generated only when the table is stationary. 
In retrospectively ECG-gated protocols (helical or spiral scanning), there is a 
continuous emission of X-rays while the table moves through the scanner 
gantry, which explains the higher exposure associated with this protocol. An 
in-depth discussion of the available scan protocols for cardiac CT is reported 
in chapter 4.1. 
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For this study we used a modified prospectively ECG-triggered protocol 
available on our second-generation dual-source CT scanner, i.e. a 
prospectively ECG-triggered high-pitch spiral acquisition protocol (Flash 
mode, Siemens, Forchheim, Germany). In this protocol, table movement and 
X-ray emission were prospectively synchronised with a phase starting at 
60% of the R-R interval. Table movement had a speed of 45cm/s, allowing for 
reduction in patient radiation exposure. Previous studies have reported 
consistency and good reproducibility of this method when compared to 
traditional scan protocols(144). 
 
3.2    The Agatston CAC Score 
The Agatston CAC score was developed by Arthur Agatston and colleagues 
(145) in the 1980s, when multiple large-scale studies for the detection of 
coronary artery calcium using a dedicated EBCT scanner were published. 
This technique relies on some assumptions: 
 Any structure with a density of 130 Hounsfield units (HU) or more, 
and having an area of 1mm2 or more, was considered a calcified focus.  
 The foci overlying the coronary arteries were considered calcified 
plaques.  
 A minimum  area of 2 to 4 pixel was considered for measurement, 
with one-pixel foci considered as noise. 
To obtain the Agatston score, the area of a calcified lesion on a 3-mm slice is 
multiplied by a density score factor from 1 to 4, which depends on the voxel 
with the highest attenuation contained in that focus. 
Density scores 1,2,3 and 4 represent the densities 130-199 HU, 200-299 HU, 
300-399 HU and ≥ 400 HU, respectively. 
 
By adding up the scores for the calcified lesions in the coronary arteries the 
total Agatston CAC score is obtained. 
 
Ranges of Agatston CAC score were used to define four categories associated 
with increasing risk of significant angiographic CAD (≥50% diameter 







Table 2: Agatston CAC score categories for general population 
CAC (Agatston) Risk Description 
0 Non-identified Minimal risk of having a cardiovascular event in 
5 years. 
1-10 Minimal Low risk of having a cardiovascular event in 5 
years. 
11-100 Mild Mild risk of having CAD exists. 
101-400 Moderate  Moderate risk of having CAD exists. 
>400 Severe There is a significant risk of having 
cardiovascular events within the next 5 years. 
CAD = coronary artery disease; 
 
3.3   Clinical Application of CAC Score 
In the last few decades, the CAC score has become an established method for 
cardiovascular risk assessment. Its role for risk stratification, and its 
prognostic value are well known. 
In the general population, coronary calcium is a marker of coronary 
atherosclerosis. Therefore, there is an association with cardiovascular events 
such as myocardial infarction, mostly related to the rupture of vulnerable 
plaques (147). 
Although this non-contrast technique only allows the detection of the 
calcified component of atherosclerosis and non-calcified plaques cannot be 
identified, a good correlation has been found between CAC score and the total 
amount of coronary atherosclerosis detected by intravascular ultrasound and 
histology (148, 149). For this reason, despite the known tendency to 
underestimate total plaque burden, CAC score is considered a reliable 
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indicator of the total amount of coronary atherosclerosis (142). CAC score 
has also been found to be more closely associated with total coronary plaque 
burden than the presence of luminal stenosis (149). An increasing amount of 
calcium in the coronary arteries correlates with an increasing probability of 
having significant, angiographically proven coronary artery stenosis (149). 
On the other hand, the total CAC score refers to the entire coronary tree and 
cannot be used to diagnose site-specific coronary luminal stenosis (150). 
 
3.3.1 Cardiovascular Risk Assessment  
CAC score has a high sensitivity and negative predictive power for 
obstructive CAD and it has been extensively validated as marker for 
cardiovascular disease. 
The association between CAC score and traditional Framingham Risk Score 
(FRS) has been evaluated. CAC score was shown to have independent 
incremental value in the prediction of events in an asymptomatic population 
(151, 152). In a large cohort of 10,377 asymptomatic individuals with cardiac 
risk factors, it has been shown (153) that not only that CAC score is an 
independent estimator of all cause mortality but also that the 5 year survival 
rate worsens as the CAC score increases from levels of ≤10 to greater than 
1.000. 
The CAC score helps in the reclassification of patients in more appropriate 
CAD risk categories. For instance, it was shown that intermediate risk 
patients with a high CAC score (>300) had a 28% 10 year rate of cardiac 
death that would reclassify them in the high-risk category (154). 
 
3.3.2 CAC Score in Asymptomatic People 
A recent meta-analysis involving more than 29,000 asymptomatic subjects 
showed that the annual event rate for those with a zero CAC score was only 
0.12% (155). A negative CAC score was also found to be more predictive of 
decreased cardiovascular events when compared to a negative stress test or 
normal intima media thickness on carotid ultrasound (156, 157). Even in 
diabetic subjects with a negative CAC score the cardiovascular risk was 
similar to subjects without diabetes (158). 
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According to the 2010 ACCF/AHA practice guidelines (159), the measure of 
CAC score was considered appropriate for the assessment of cardiovascular 
risk in asymptomatic adults with low-intermediate risk (6-10% 10-year risk), 
intermediate risk (10-20% in 10-year risk) and diabetic patients. 
In practice, a negative CAC score suggests that the presence of atherosclerotic 
plaque is unlikely. Conversely, the presence of coronary calcium in an 
asymptomatic subject does not provide a rationale for revascularisation, but 
it can identify subjects with preclinical atherosclerosis who might benefit 
from risk factor modifications, potentially medical treatment and/or further 
testing (160). Therefore, as a specific marker of atherosclerosis, CAC score 
has been consistently proven to be valuable for prognostication, 
discrimination, calibration and reclassification for cardiovascular disease in 
selected subjects (161). In general, however, the unselected use of CAC 
screening of the entire population is not recommended by current practice 
guidelines (162, 163). 
 
3.3.3 CAC Score in Symptomatic Patients 
The role of CAC score in patients with chest pain and suspicion of CAD has 
been shown in several studies, particularly its role as a gatekeeper for further 
testing (164). In particular, when a zero CAC score was used to identify 
patients without obstructive CAD, the test had a sensitivity of >95% and a 
negative predictive value (NPV) of 99% (164). 
The UK-based National Institute for Health and Care Excellence (NICE) has 
supported the use of CAC score as a first line test for symptomatic patients 
with stable chest pain of recent onset and a low (<30%) pretest probability of 
CAD (165). It has also been suggested that CAC score may have a role in the 
management of patients with low-risk acute chest pain. Patients with 
negative troponin, no ECG changes and a zero CAC score could be discharged 
without further testing, in keeping with the 2010 UK NICE guidelines (164, 
166). The American Heart Association scientific statement (167) reports that 
“a negative test (zero CAC score) makes the presence of atherosclerotic 
plaque, including unstable and vulnerable plaque, highly unlikely, and 
consistent with a low risk (0.1% per year) of cardiovascular events in the 
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next 2-5 years” (160). Although in the more recent UK NICE guidance 
published in 2016 (168) the use of CAC score has been superseded by CTCA due 
to the recongnised risk of underestimating non-calcified plaque by the CAC score, 
the added benefit patient associated with this approach cannot yet be established 
 
3.4      CAC Score in ESRD 
At present there are relatively few published data regarding CAC score in the 
ESRD population. It has been reported that CAC score was significantly 
associated with future cardiovascular events, cardiovascular death and all-
cause death in patients on dialysis without cardiac-related symptoms (106, 
113, 169, 170). It has also been shown that the severity of CAC score at the 
time of initiation of dialysis was a significant predictor of all cause mortality; 
in particular, a baseline CAC score >400 was associated with a greater than 
four-fold increase in mortality (113). 
It is important to highlight that in this population a very high CAC score may 
be associated with cardiovascular death and all cause death, but this may not 
always imply the presence of underlying obstructive luminal CAD (171-174). 
The progression of coronary calcifications also plays an important role in the 
mortality of this group of patients with relation to the treatment of 
hyperphosphatemia. Block at all (170) not only confirmed that the baseline 
CAC score was a significant predictor of mortality, but also demonstrated that 
phosphate binder choice and mineral metabolism were linked with mortality 
in hemodialysis patients. The choice of calcium phosphate binders as 
opposed to sevelamer in the treatment of hyperphosphatemia was associated 
with a doubling of mortality. Sevelamer is used to treat hyperphosphatemia 
and it is phosphate binding drug which prevents the absorption of 
phosphate(175). In the ESRD population coronary calcification can be 
present in both the medial muscular layer and in the subintimal layer of the 
vessel wall, but only intimal calcifications are a specific marker of 
atherosclerosis (104). Both types of calcification are captured when 
measuring the CAC score. Medial calcifications contribute to the overall 
calcification, indicate vascular damage secondary to uraemia, but are not 
associated with atherosclerosis (104). For this reason, it has been suggested 
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that the normal cut-off value of ≥400, indicative of an elevated 
atherosclerotic burden in the general population, may not apply to ESRD 
patients. At present there is no unequivocal data suggesting the best CAC 
score cut-off in this population to predict cardiovascular events and 
mortality. 
A non-negligible proportion of ESRD patients can have zero CAC score (174), 
which makes significant CAD very unlikely. Similar to the pattern observed in 
non-ESRD patients, also in ESRD patients a baseline zero CAC score is 
associated with a significantly lower rate of cardiovascular events compared 
to patients with positive CAC score (CAC score >1) (113). In one study (169) 
no cardiovascular deaths were observed at a mean follow-up of 48.8 months 
in the group of ESRD patients with zero CAC score on chronic haemodialysis. 
Moreover no development of calcification has been noted in 18 months 
follow-up after dialysis initiation in one study, regardless of the choice of 
phosphate binders (170).  
For these reasons, a zero CAC score can be considered a valuable practical 
diagnostic result in ESRD patients without cardiac symptoms. A zero CAC 
score implies that further testing for coronary atherosclerosis or CAD-related 
ischaemia could be avoided (169, 174). 
 
3.5 Warranty Period of Zero CAC Score 
Several studies have stated the favourable prognosis of zero CAC score in 
maximum 5 years follow-up (155, 176, 177). Importantly, a recent study 
examined a much longer-term prognostic utility of CAC score in a large 
cohort of asymptomatic individuals with cardiac risk factors and without 
known CAD (152). The authors performed a 15 year follow-up on 9,715 
individuals (of whom 4,864 had zero CAC score) and showed that a zero CAC 
score was associated with a low risk of mortality (in both sex groups) for 
more than 15 years in subjects younger than 60 years of age, and for 14 years 
for subjects 60 years of age or older (low-risk and intermediate-risk groups). 
A zero CAC score was associated with a warranty period of 5-6 years for high 
risk patients. This period is longer compared to that of low-risk or 
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Chapter 4: Computed Tomography Coronary Angiography (CCTA) 
 
4.1     Technical Aspects and Contemporary Technology 
4.1.1 Computed Tomography Basics and Technique 
Computed tomography allows the evaluation of the human body in transaxial 
sections, and unlike linear tomography, it is able to generate images which 
are not influenced by the neighbouring regions of the body. It was introduced 
in the 1970s and was originally called computed axial tomography (CAT 
scanning).  
The basic components of a CT scanner are the x-Ray tube, collimator and the 
detector array, which are installed on a rotating gantry.  The patient lies on a 
table which is moved longitudinally through the gantry aperture and usually 
the plane of the gantry rotation is perpendicular to the table’s long axis. With 
that said, some scanners can tilt the gantry up to 30 in order to have images 
acquired at an angle of the body (main application is CT of the head)(178). 
The X-ray tube is parallel to the rotation axis of the scanner and produces the 
X-ray beam; the collimator is mounted on the X-ray tube and its main role is 
to try to limit the scatter radiation in order to have accurate images(178). 
The detectors are situated opposite the X-ray tube and they capture the X-ray 
beam after its passage thought the patient’s body. The signal measured by 
the detectors is the result of the weakening of the X-ray beam when it passes 
though the different body tissues. When the attenuated X-ray beam reaches 
the detectors, it hits a “scintillator” which will then convert the detected X-
rays into light. The light will then be converted into electricity by 
photodiodes, and a converter produces digital data and transmits them to the 
computer for analysis. The computer then translates the measurements into 
individual section images(178). 
Each bidimensional CT image is usually calculated on a 512x512 matrix of 
pixels, ie. bidimentional picture elements.. More correctly though, a cardiac 
CT dataset shuould be  described as an imaging volume made up of voxels, ie. 
three-dimensional picture elements that have a depth equal to the slice 
thickness(179).  The multiple projections obtained by the rotation of the 
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gantry provide the attenuation values of the voxel and these attenuation 
values are assigned to the pixel that forms the image(179). As a general rule, 
the more projections obtained, the better the image quality. For image 
reconstruction, complex mathematical algorithms are required. The vast 
majority of the algorithms are based on the back-projection method. In this 
algorithm, the overall X-ray attenuation of a projection is assigned to each 
voxel along the X-ray beam and then the value of the voxel results from the 
sum of the values of all the projections along the X-ray coming thorough the 
voxel. The downside of this method is that images are blurred. In order to 
compensate for this and obtain better image quality, a convolution kernel is 
used before back-projection (this method is called filtered backprojection-
FBP)(180). A convolution kernel is a filter that will adjust the value of a voxel 
according to the value of the adjacent voxels. 
Although modern FBP methods are capable of quick reconstructions, they 
have several limitations. Image noise, poor contrast resolution and streak 
artefacts are limitations of FBP (180).  This is mainly due to variations in the 
photons across the imaging plane, which ultimately results into an inverse 
relationship between noise and radiation dose when FBP is used (180). 
Recently, the introduction of  more sophisticated reconstruction algorithms 
called collectively iteractive reconstruction (IR) made it possible to lower 
patient’s raadiation exposure without compromising image quality (refer to 
section 4.1.6) 
 
The first types of CT scanners for clinical use were capable of axial scanning 
only. These systems worked using the step and shoot technique in which the 
gantry had to stop after each 360-degree rotation. The gantry could not 
rotate continuously around the patient as in spiral or helical scanning. The 
main reason for this was that the gantry received its electrical supply via 
hard wires.  
A dramatic advantage was gained with the introduction of the slip ring 
technology. Following this development, the gantry could rotate continuously 
around the patient with the table translating without interruption. This 
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technique has been referred to as helical, volume, or spiral scanning. The 
main advantage of this technique was a significant increase in scan speed, 
which was increased even further with the introduction of the multislice or 
multidetector technology. The latter technology enabled scanning several 
slices per revolution thus including larger parts of the body in the scan in 
reduced time. 
Several CT scanner generations can be described as follows. 
First Generation: these scanners used the “translate and rotate movement” 
meaning that the tube and detector moved in a series of sweeps and rotations 
around the patient. The X-ray tube produced a pencil-like X-ray beam, which 
was detected by one single detector. The average scanning time for one slice 
was 5 minutes (181). 
Second Generation: this generation of scanners were still using a translate-
rotate motion but they were equipped with multiple detectors and the X-ray 
beam was fan shaped. This allowed to cover a larger area and the scan time 
was reduced to roughly 90 seconds per slice (181) .  
Third Generation: the main advantage was achieved by the use of a pure 
rotational motion instead of the translate-rotate one. This was accomplished 
with a wide X-ray fan-beam which was able to cover the entire patient body,  
using multiple detectors to detect the X-ray beam. Detectors and X-ray were 
linked, and were able to rotate together around the patient.  This resulted in 
a reduction of scanning time to 20 seconds per slice (178).  
Fourth Generation: the main advantage was achieved by using an outer fixed 
detector array system, with the X-ray tube only rotating around the patient 
with the slip-ring technology. The scan time per slice was significantly 
shorter (1 slice per second) (181). This technology is however superseded in 
current CT technology. 
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Modern CT scanners are based on third generation configuration: a wide X-
ray beam is detected by a multi-element detector array. Both the X-ray tube 
and detector array rotate around the patient. 
Cardiac CT became possible with the first generation of multi-element CT 
scanners that were capable of cardiac synchronised acquisition. This was 
with 4-detector CT (1999). Cardiac CT was then more widely validated in 
patients with 16-detector CT scanners (2000-2003). Sixty-four detector CT 
(2004) showed improved robustness for clinical applications and is now 
considered the minimal technical requirement for performing cardiac CT.  
With the dual-source technology there has been improvement in temporal 
resolution.. This technology uses two X-ray tubes and two detectors arranged 
at 90° angles instead of a one single X-ray tube (single source scanner). The 
two X-ray tubes and detectors rotate simultaneously reducing image 
acquisition to half of the time required with single source technology. This 
permits reconstruction of cross-sectional images at one quarter of the gantry 
rotation time (182). It has been shown that image quality is significantly 
better with dual source scanners when compared to single source scanners, 
even at higher heart rates. Three iterations of dual source CT scanners have 
been introduced so far, all by a single manufacturer (Siemens): the Somatom 
Definition (2006), the Somatom Definition FLASH (2009) which was used in 
this project, and more recently the Somatom FORCE (2015). Although some 
authors suggested that the use of beta-blockers may become unnecessary 
when using dual source CT technology (182), this issue is still debated and 
the majority of practitioner still enforce accurate heart rate control for 
cardiac CT even in the availability of a dual source CT scanner.  
At present, invasive coronary angiography still remains the gold standard for 
CAD assessment because of its spatial and temporal resolution (refer to 
section 4.1.3), however, over the last decade there have been dramatic 
advances in both CT scanner and software technologies that have achieved 
adequate volume coverage, sub-millimeter spatial resolution, and heart-
freezing temporal resolution which permit accurate depiction of both cardiac 
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structures and coronary arteries (183). While first reports on the safety of 
cardiac CT date to 1999 with 4-slice CT scanners (184), the technique was 
proven feasible using 16- and 64-slice technology (185). The general 
consensus in 2017 is that 64-slice CT technology represents the bare 
minimum technical requirement to provide a clinical service of cardiac CT.  
 
4.1.2 ECG-synchronization and Scan Protocols 
Coronary arteries are small and rapidly moving vessels and even at slow 
heart rates exhibit significant translational motion. The translational motion 
speed is up to 60mm/s for the right coronary artery and 20-40mm/s for the 
left anterior descending and circumflex arteries (186). ECG synchronisation 
is critical to minimise the motion artefacts and acquire data at the right 
period of the cardiac cycle. Beta-blockers administration before the scan is 
often needed and recommended to obtain a low heart rate preferably below 
65 beats/minute. 
Across different vendors, the most widely used ECG-synchronization 
protocols for CCTA include retrospective ECG-gating and prospective ECG-
triggering: 
The retrospective ECG-gating mode consists of a helical acquisition 
(patient/table continuously advanced during the gantry rotation) with the X-
ray tube turned on throughout the cardiac cycle (Table 3 and Figure 5) (187). 
The X-ray tube current can be reduced in the phases of the cardiac cycle not 
used for reconstruction of high resolution images to limit the patient’s 
radiation exposure, which is called ECG-dependent X-ray tube current 
modulation (see also section 4.1.6.) 
The prospective ECG-triggering mode involves axial acquisition (the table 
intermittently advances) with the X-ray tube on only for a specific period of 
the cardiac cycle, usually the mid-diastole, or a wider window (usually 40-
70% of the cardiac cycle) if the heart rate is not optimal (Table 3 and Figure 
5) (183). 
The high-pitch spiral CT protocol has been introduced in the latest 
generations of dual-source scanners. This protocol uses a very fast table 
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speed (45m/s) in order to image the whole heart in one heart beat (Table 3 
and Figure 4) (183).  
In scanners with very wide detector (e.g. 320 slices) one gantry rotation 




Table 3: CCTA protocols. Adapted from (188) 
Retrospective ECG-gating Protocol 
Advantages Disadvantages 
 All heart rates    
 All rhythms (also AF and multiple 
VES)  
 Both systolic and diastolic images  
 Free phase selection  
 Overlapping consecutive images  
 Functional analysis  
 High dose (11-19 mSv)  
 
Prospective ECG-triggered protocol 
Advantages Disadvantages 
 Low dose (1.5-4 mSv)  
 Regular and low heart rate  
  
 Vulnerable for HR irregularity and 
variability  
 No functional analysis  
High-pitch spiral CT protocol 
Advantages Disadvantages 
 Low dose (<1-2 mSv)  
 Relative low contrast material 
amount  
 Overlapping images  
 No stack artefacts  
 
 Low HR (< 60bpm) required → if 
>65 bpm: β-blocking  
 Only diastolic images  
 Vulnerable for HR irregularity and 
variability  
 Only 33.2 cm FOV  
 Images along the Z-axis come from 







Figure 4: Schematic drawings of retrospective gating (A), prospective 
triggering (B) and high-pitch spiral(C) techniques. Adapted from (188) 
 
 
4.1.3. Temporal Resolution and Spatial Resolution 
Because of the small size of coronary arteries and their movement during the 
cardiac cycle a high spatial and temporal resolution are required in order to 
obtain adequate image quality (189). 
Spatial resolution is defined as the minimum distance at which two signals 
can be identified as separate (190). Temporal resolution is the time it takes 
to acquire data for the reconstruction of one image (191). 
 
 48 
4.1.4. Reconstruction and Post-processing 
Data used for image reconstruction are obtained during the relative “motion-
free” period of the cardiac cycle (mid-to-end diastole and end-systole) and 
this is usually obtained in stable heart rates (192). 
Depending on the protocol used, reconstruction of consecutive datasets 
(usually every 5%-10%) of the cardiac cycle allows evaluation of the 
coronary arteries in different moments of the R-R interval. The evaluation of 
left ventricular systolic and diastolic volumes is also possible if the scan is 
being acquired using a retrospectively-gated spiral technique, or a wide 
prospectively-triggered technique, thus allowing the estimation of the left 
ventricular ejection fraction. A tailored reconstruction field of view (FOV) 
which includes the heart and the descending thoracic aorta is ideal for image 
evaluation, optimizing the utilization of the 512x512 pixel matrix. 
The most reliable and widely used post-processing technique for image 
visualisation and analysis is multiplanar reconstruction (MPR), which allows 
to accurately visualise the whole coronary tree in multiple planes, including 
arbitrary planes, in order to assess the degree of luminal narrowing. Curved 
MPR’s are also useful to visualise images of the coronary arteries along the 
vessels’ centrelines. 
 
4.1.5. Patient Selection and Preparation 
Important contraindications to a CT scan may include pregnancy, known 
allergy to iodinated contrast and severely impaired renal function. 
Even with new generation scanners, obtaining good quality images can be 
challenging. Artefacts can occur if patients are not adequately prepared and 
not compliant with the breathing instructions. It is recommended to fully 
explain the procedure to the patients in order to reduce anxiety, which in 
turn can have an impact on the heart rate. Artefacts are mainly caused by 
inability to cope with the breath-holding instructions during the scan, as well 
as fast and/or irregular heart rates. Patients should be able to perform an 
adequate breath-hold maneuver for as long as the expected scan time. Deep 
breaths should also be avoided as it may result in a Valsalva manoevre, which 
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can be the cause of low contrast attenuation in the coronary arteries due to 
“trapping” of the contrast bolus in the pulmonary circulation.  
Sublingual nitroglycerin is given in order to dilate the coronary arteries and 
enhance confidence is coronary stenosis assessment, but disadvantages may 
include reflex tachycardia and severe headache in some patients. 
 
4.1.6. Radiation Exposure 
Radiation dose has become a growing concern with the increasing use of 
radiological testing and particularly CT. The radiation dose of CCTA can vary 
on the basis of the scanner generation/model, and the protocols used.  
The most commonly used parameters to evaluate radiation dose are: 
-Volume CT dose index (CTDIvol):  this is an indicator of the scanner 
radiation output and its units are milligrays (mGy). This parameter does not 
provide information on the radiation dose to the patient (193). 
-Dose-length product (DLP): describes the linear extent of the exposure to 
the patient and it is obtained by multiplying the CTDIvol times the 
centimeters of coverage. DLP units are mGy-cm(193) .  
- Absorbed dose (patient dose): it describes the quantity of ionizing radiation 
deposited in tissue and it is expressed in milligrays (193).  
- Effective dose takes into account the differing type and energy of the 
radiation source and also the biological harm from exposure to a particular 
organ (tissue weighting). The effective dose is primarily used  to define the 
risk of a health detriment due to the stochastic effects of ionising radiation to 
a population, rather than the calculation of risk for a specific individual (194). 
The risk coefficients used in calculating effective dose were derived from a 
cohort that included both sexes and all ages and depended primarily on the 
excess risk observed in survivors of the Japanese atomic bombings. The 
values are a broad estimate of risk for an average adult hermaphrodite 
phantom, which is a fairly unrealistic description of the human body (195). 
Although the effective dose is not applicable to any single individual, it is an 
extremely useful parameter for comparing and optimising imaging 
procedures that use ionising radiation. 
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Multicentre studies carried out between 2005 and 2007 have reported a 
variation in CCTA effective dose ranging from 4mSv to 30mSv (196, 197). 
In order to minimise the dose, several methods are available (183). These 
include: 
1) Limitation of the scan range along the z-axis. 
2) Tube current-time product (milliampere-second or mAs) is the product of 
the X-ray tube current and the CT scanner exposure time per rotation (in 
seconds). The increase of the mAs results in  an increase of the radiation 
dose. All the scanners have the possibility to actively modulate the mAs 
during the scan in order to apply radiation efficiently. In practice, the scanner 
will produce lower radiation in regions of lower attenuation and apply higher 
radiation only for the higher attenuation regions(193). Moreover, every 
vendor gives the possibility to modulate radiation dose according to patient’s 
size. We used this technique in our study which is called CareDose4D for 
Siemens. 
3) Use of ECG-dependent current modulation to reduce the tube current in a 
specific part of the cardiac cycle. 
4) Tube voltage (kV): indicates the peak energy of the X-ray photons beam in 
kilovolts. Lowering the kV will result in a radiation dose reduction as well as 
in greater contrast-to-noise ratio depiction of iodinate contrast in average-
sized and small patients. The downside of a lower kV is an increased image 
noise, which can affect the quality of the images(193). Recently, dedicated 
software identify the most appropriate tube voltage according to patient’s 
attenuation, for a given target contrast-to-noise ratio to be achieved in the CT 
images. 
5) Prospectively ECG-triggered scanning protocol (refer to section 4.1.2). 
6) Correct patient centering: it has been demonstrated (198) that 
miscentering the patients can result into an increase of the radiation dose. If 
the patient is too close to the tube, the scout or localizer will be larger and the 
automated tube current modulation system may incorrectly increase the mAs 
output. 
6) Pitch: it is a parameter used in helical CT only. It is described as the ratio 
of table speed, in centimeters per 360° gantry rotation, to the total nominal 
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collimated x-ray beam width in the z direction. Given a constant output, as 
the pitch increases, the radiation dose proportionally decreases. In cardiac 
imaging the high pitch technique can significantly reduce the dose. The 
acquisition of the all heart can be achieved in one heartbeat with a smaller 
bolus of contrast (199). 
7) Iterative Reconstruction is a novel approach used to decrease image noise 
without compromising on image quality for reduced-dose CT. 
Image noise is determined in part by the range of mA used. Lowering the mA 
range translates into patient dose reduction at the expense of greater image 
noise. At lower current level iterative reconstruction can selectively reduce 
image noise by perforing multiple iterations of the reconstuction process 
(200). This is therefore a “statistical reconstruction” method which uses 
reiteration in the reconstruction process to remove noise. 
 
4.2      Clinical Utility of Coronary Computed Tomography Angiography 
4.2.1    Diagnostic performance 
Diagnostic performance evaluates the ability of a qualitative or quantitative 
test to accurately classify individuals into categories (e.g. condition positive 
and negative)(201) and it can be appraised comparing the agreement 
between the outcome of the test and a reference standard for the condition. 
Several studies have used coronary angiography as the reference to evaluate 
the diagnostic performance of CCTA in different patient groups (e.g. by age 
and gender) or different clinical scenarios (e.g. stable chest pain and acute 
chest pain) (185, 202, 203). These studies have focused mainly on sensitivity 
and specificity of CCTA. 
Sensitivity is defined as the proportion of true positives correctly identified 
as such and it is obtained dividing the true positives by the sum of true 
positive and false negatives. The specificity is defined as the true negatives 
correctly identified as such and it is calculated dividing the true negatives by 
the sum of false positives and true negatives. (201). In order to interpret the 
results of a test it is also important to know the probability that a 
subject/patient is truly positive if a test is positive and truly negative if the 
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test is negative. The chance that this is the case is provided in the positive 
and negative predictive values of a test (201). 
 
According to a recent systematic review, the sensitivity of CCTA in the 
detection of coronary artery stenosis compared to invasive angiography was 
~98% (204). When sensitivity was examined according to age group, 
sensitivity remained largely unchanged (range: 95–99%). A greater degree of 
variability, however, was observed in the analysis of specificity. Specificity 
varied widely by age group ranging from 91% in studies with a mean patient 
age <59 years to 77% in studies with a mean patient age >62 years. A 
potential explanation is that CCTA may have lower specificity in the elderly 
due to higher levels of coronary artery calcification in older patients (205) 
leading to false positive findings, i.e. overestimation of stenosis severity. 
 
It is well known that the presence of coronary calcification makes the 
assessment of the coronary arteries difficult. Kruk et al (206) investigated 
this aspect and found that:  
- CCTA underestimates the coronary lumen area in presence of calcium. It 
was already known that calcium makes the evaluation of the lumen 
difficult resulting in a reduction of accuracy (207, 208) but the authors 
also found a correlation between lumen underestimation and smaller 
lumen (206).  In summary, in smaller segments of the coronary arteries 
even artifacts caused by moderate calcifications may result into 
diagnostic errors (206). 
- Although less common, CCTA can also overestimate the coronary lumen 
and the authors hypothesized that this may be due to the presence of 
small and less dense calcification which cannot be detected by CT (206). 
These findings found conformation in another study by van der Giessen 
et al. (209), where the authors found that upto 50% of the calcifications 
detected on intravascaulr ultrasound could not be seen on contrast 




When compared to functional testing (stress SPECT, PET, 
echocardiographycardiography or CMR) CCTA was found to be the most 
accurate test to detect significant anatomical CAD (defined by invasive 
coronary angiography as >50% diameter reduction in the left main or >70% 
elsewhere or between 30% and 70% with a fractional flow reserve of ≤0.80) 
in a European population with stable chest pain and low prevalence of 
disease (210). It could be argued that this study used a hybrid, 
predominantly anatomical reference standard, so it was not surprising that 
CCTA as an anatomical test yielded closer results to the reference standard 
compared to the other imaging modalities included in this study. 
 
A strong feature of CCTA, consistently confirmed across different studies, is 
its high negative predictive value (NPV) (167). CCTA has an excellent NPV 
(virtually 100%) in the exclusion of CAD (≥50% diameter reduction on 
angiography) (185, 211, 212).  
 
CCTA however is an anatomical test performed in resting conditions and as 
such cannot provide information about the presence of stress-inducible 
ischaemia (213). Although CCTA can be used in clinical practice to rule in and 
rule out CAD, when CAD is detected the functional significance of coronary 
stenosis (ischaemia) cannot always be extrapolated based on coronary 
anatomy alone and in resting conditions. A further functional (stress) test 
may be required to guide patient management, particularly coronary 
revascularisation with either percutaneous coronary intervention (PCI) with 
stent placement, or surgical coronary artery bypass grafting (CABG) (214, 
215). 
 
In the FAME study (216) the relationship between anatomical coronary 
artery stenosis and its functional severity has been investigated by 
measuring the fractional flow reserve (FFR). FFR is a method used during 
invasive coronary angiography that uses sensor-tipped pressure wires to 
measure the maximal pressure in a coronary artery distal to a stenosis and in 
the ascending aorta. The ratio between these two pressure measurements is 
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used to establish the functional severity of a coronary stenosis, with 
functional significance defined by FFR <0.80. 
The most important finding of this study was that one cannot rely just on the 
anatomy to identify ischaemia-producing lesions when assessing stenosis 
between 50-90%. Only in the presence of a coronary stenosis category >90%, 
visual assessment corresponds quite well to the lesion’s capability of 
inducing myocardial ischaemia. 
 
In a recent meta-analysis, Danad et al (217) investigated the diagnostic 
accuracy of different cardiac imaging methods in the assessment of 
hemodynamically significant CAD using fractional flow reserve (FFR) as 
reference standard (217). This study found that CMR was the most accurate 
test to identify hemodinamically significant CAD, while stress 
echocardiographycardiography and SPECT showed lower accuracy. 
Anatomical tests such as invasive coronary angiography and CCTA had low 
specificity (217). This was not surprising given the proven weak relationship 
between degree of luminal narrowing and ischaemia.  The accuracy however 
improved when anatomical tests were followed by functional assessment, eg. 
with either stress echocardiographycardiograohy, SPECT or FFRct (see 
chapter 9) (217). 
 
4.2.2    Prognostic Value 
The extent and severity of anatomical CAD on CCTA correlates with the risk 
of cardiac events and death from cardiac cause (218-220). A recent meta-
analysis pooled together the results of 18 prospective and retrospective 
cohort studies in patients with suspected or known CAD (n = 9592) (34). The 
pooled annualised event rate in patients with a normal CCTA was very low 
for major adverse cardiac events (MACE) (0.17%) as well as 
death/myocardial infarction (0.15%). The rates increased incrementally 
when stratified by none, non-obstructive (<50% coronary diameter 
reduction), and obstructive (>50% coronary diameter reduction) CAD 






Figure 5. Percentage of annualised revascularisation (Revasc), event rates for combined 
major adverse cardiac events (MACE), death (all-cause)and  myocardial infarction 
(MI),stratified by CCTA diagnosis of no coronary artery disease (CAD), non-obstructive CAD 
(<50% stenosis), and obstructive CAD (>50% stenosis). All groups were significantly 




4.2.3    Clinical Decision Making 
The role of CCTA to exclude obstructive CAD is nowadays widely recognised. 
However, there are limited data as to whether CCTA would also have the 
capability to differentiate high-risk patients who may benefit from 
revascularisation from patients who would be suitable for conservative 
management based on the CCTA findings. 
This aspect was investigated by Min and colleagues (222) who studied 
retrospectively 15,223 patients without known CAD undergoing CCTA from 
the CONFIRM study. According to this study, the anatomical severity of CAD 
detected by CCTA predicted the clinical outcomes after revascularisation. In 
particular, the authors came to the following conclusions: 
-revascularisation in subjects with high-risk CAD detected on CCTA (defined 
as a ≥50% luminal diameter narrowing in a major coronary artery) is 
 56 
associated with a significantly lower rate of all-cause mortality (compared 
with medical therapy alone). 
- subjects with lesser forms of CAD do not benefit from revascularisation. 
It is, however, important to highlight that this was a retrospective non-
randomised study and patients received treatment based on a mix of 
diagnostic tests, not solely based on CCTA. Importantly, there was no 
treatment adjudication based on the CCTA findings. For this reason, further 
randomised trials are necessary to confirm these findings (222, 223). 
More recently Douglas et al in the PROMISE trial (224) studied a large 
symptomatic population in order to evaluate the better diagnostic strategy 
(anatomical versus functional testing) to assess CAD with death, myocardial 
infarction, hospitalisation for unstable angina or major procedural 
complication as a composite primary endpoint. As secondary endpoints they 
evaluated the radiation dose and the incidence of non-obstructive CAD 
detected on the coronary angiogram within the different strategies. The 
“anatomical” strategy using CCTA as first line test was not found to be 
associated with better clinical outcomes than the “functional” strategy and 
both strategies showed excellent midterm prognosis(224). CCTA strategy 
was associated with a lower incidence of non-obstructive CAD on the 
coronary angiogram, a 34% reduction in death and non-fatal MI at 12 months 
and with a reduction in radiation dose when compared with MPS (224). The 
study was not able to show the definitive superiority of  the anatomical 
strategy versus the functional strategy, most likely due to short follow-up 
time (1 year) (225), but this was demonstrated in another large scale study 
named the SCOT-Heart (226). 
In this randomised controlled trial the authors focused on the role of CCTA in 
patients with stable chest pain in order to assess the effect of CCTA on the 
diagnosis, management, and outcome. The results showed that adding CCTA 
to standard clinical care “markedly clarified diagnosis of angina due to 
coronary heart disease”. Moreover, a reduction in further stress testing was 
observed, and patients could also benefit from more focused treatments 
which are apparently associated with reduction in fatal and non-fatal 
myocardial infarction. Although the authors observed an increase in 
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coronary angiographies in the vast majority of patients, the ICA showed 
obstructive coronary heart disease, including those with severe triple vessel 
disease . More recently Williams et al (227) in the SCOT-Heart trial 
demonstrated that the changes in diagnosis as result of CCTA findings 
resulted into  more appropriate selection of patients for ICA and also resulted 
into better implementation of preventive therapies. 
 
4.2.4    Cost-effectiveness   
Cost-effective is anything effective and/or beneficial in relation to its cost. To 
assess whether a medical procedure or a test is cost-effective a comparison of 
its relative costs and outcomes against another test can be performed and 
this is defined as cost effectiveness analysis. The evidence regarding the cost-
effectiveness of CCTA is limited. 
A systematic review regarding the cost effectiveness of CCTA for coronary 
artery disease assessment was published in 2014 by Zeb et al (228). The 
authors analysed the literature from 2000 onwards and included randomised 
controlled trials, prospective and retrospective non-randomised comparative 
studies, decision analytic models, technology reports and case series which 
mentioned the cost-effectiveness, comparative effectiveness and downstream 
test utilisation associated with CCTA.  The authors came to the following 
conclusions: 
1) CCTA may be a cost-effective strategy (either as initial test or a secondary 
test to other modality) for initial evaluation of patients with 10-50% CAD 
prevalence in both near-term and long-term diagnostic periods. 
2) For patients with CAD prevalence of >70% a strategy with initial invasive 
coronary angiography is more cost-effective but CCTA is still a cost-effective 
strategy when performed as a gatekeeper test before ICA in case of an 
equivocal stress test. 
3) CCTA was also found to be cost-effective for evaluation of low-risk 
(defined as <30% CAD prevalence) patients presenting to the emergency 
department with acute chest pain. 
More recently Genders et al (229) focused their analysis on the optimal 
image strategy for  stable chest pain patients with intermediate probability of 
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CAD from the prospective of USA, UK and the Netherlands. The authors found 
that in USA and Netherlands the most cost-effective strategy would include 
CCTA as first line test followed by stress imaging test if at least 50% diameter 
stenosis is found in at least one coronary artery; invasive angiography would 
be the last test if revascularization is needed. In the UK, for men, the best 
strategy was full medical therapy if moderate narrowing (50-69% diameter 
reduction) was found on CCTA. For UK women the best strategy was stress 
echocardiographycardiography as first line test followed by invasive 
angiography if a stress echocardiographycardiography shows mild or 
moderate induced ischemia.  Although some differences were found between 
the USA, UK and Netherlands, the authors concluded that CCTA was cost-
effective as triage test for low-to-intermediate risk 60-years-old patients with 
non-acute chest pain.   
  
4.3     Clinical Applications of CCTA 
The 2013 ESC guidelines on the management of stable coronary artery 
disease (230) and the 2014 ESC/ European Association of Cardiothoracic 
Surgery (EACTS) guidelines on myocardial revascularisation (231) are recent 
European documents that focus on the role of CCTA as non-invasive test for 
CAD screening.  
According to these documents the main clinical indications for CCTA are as 
follows : 
Guideline 2013 European Society of Cardiology Guidelines on the 
Management of Stable Coronary Artery Disease(230) : 
 Coronary CTA should be considered as an alternative to stress 
imaging techniques for ruling out stable CAD in patients within the 
lower range of intermediate pre-test probability (15-50%) for stable 
CAD in whom good image quality can be expected. 
 Coronary CTA should be considered in patients within the lower range 
of intermediate pre-test probability (15-50%) for stable CAD after a 
non-conclusive exercise ECG or stress imaging test or who have 
contraindications to stress testing in order to avoid otherwise 
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necessary invasive coronary angiography if fully diagnostic image 
quality of coronary CTA can be expected. 
 Coronary calcium detection by CT is not recommended to identify 
individuals with coronary artery stenosis. 
 Coronary CTA is not recommended in patients with prior coronary 
revascularisation. 
 Coronary CTA is not recommended as a screening test in 
asymptomatic individuals without clinical suspicion of CAD. 
 
Guideline 2014 ESC/EACTS Guidelines on myocardial revascularization: The 
Task Force on Myocardial Revascularization of the European Society of 
Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery 
(EACTS)(231): 
 Coronary CTA is indicated to rule out CAD in symptomatic patients 
with intermediate pre-test probability (15-85%) for CAD. 
 Coronary CTA is contraindicated to rule out CAD in asymptomatic 
patients. 
 Coronary CTA is contraindicated to rule out CAD in symptomatic 
patients with high pre-test probability (>15% or >85%) for CAD. 
 CT angiography should be considered before valve surgery in patients 
with severe valvular heart disease and low probability for CAD or in 
whom conventional coronary angiography is technically not feasible 
or of high risk. 
 Electrocardiogram-triggered CT scans or epiaortic scanning of the 
ascending aorta should be considered in patients over 70 years of age 
and/or with signs of extensive generalised atherosclerosis 
 
According to the UK NICE 2010 guidance for the evaluation of patients 
presenting with stable chest pain of recent onset (165, 232), CCTA was 
recommended for diagnosis and risk assessment of symptomatic patients 
with low-intermediate risk or pretest probability of CAD (10-29% estimated 
pre-test likelihood of CAD). This guideline was revised at the time of 
preparation of this thesis. The new NICE guidance update issued in 2016 
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(233) recommends CCTA as first line imaging test is patients with stable 
chest pain suspected for CAD regardless of the pre-test probability of disease 
estimated on clinical grounds. 
Due to its extremely high negative predictive value (234) there is consensus 
that CCTA is considered appropriate as a first line test in individuals with 
symptoms, sex and age suggestive of low-to-intermediate pretest probability 
of CAD. A normal CCTA rules out presence of obstructive CAD and this 
applies to both patients with stable chest pain and those suspicious of ACS 
(183). 
 
The use of CCTA in emergency departments has been evaluated in several 
studies and, in summary it was found that, similarly to the non-acute 
patients, a negative study is associated with an extremely low event rate 
(235). 
From 2006 to 2012, observational studies (236-239) focused on the role of 
CCTA in the emergency department and all results were consistent with the 
ROMICAT I study(238) . The ROMICAT I showed that while a negative CCTA 
excludes ACS with high sensitivity (100%), acute coronary syndrome cannot 
be ruled-out in the presence of coronary plaques and this results in a 
reduction of the CCTA specificity (only half of patients with obstructive 
coronary disease defined as >50% diameter reduction on CTA, have acute 
coronary syndromes). 
Several randomised effectiveness controlled trials (240-242) have explored 
safety and economic performance of cardiac CT in acute chest pain where 
CCTA was proven to be adverse event free (241) or having a low adverse 
event rate (240, 242). More importantly, examining the whole population of 
these three studies (> 3000 subjects), none of the patients were discharged 
with missed diagnosis of ACS. The same studies also highlighted how the 
CCTA, performed in acute chest pain, allows a rapid triage reducing 
unnecessary hospital admissions and reducing the time to discharge. 
Moreover, the ROMICAT II trial authors (243) showed that high risk plaques 
detected on CCTA (positive remodelling, <30 HU, spotty calcium and napkin-
ring sign which can be seen in a high risk plaque as a necrotic core covered 
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by a thin cap) in patients presenting at the emergency department with acute 
chest pain but without objective evidence (on initial ECG and troponin) of MI 
or myocardial ischaemia, improves the early diagnosis of acute coronary 
syndromes independently to the presence of significant CAD and clinical risk 
assessment. The suboptimal accuracy of CCTA in detecting ACS using the 
traditional criteria of significant stenosis may result in an increased number 
of downstream tests and interventions (243), but the accuracy can be 
improved by adding the high-risk plaque assessment. This area is a focus of 
intense research, and criteria for implementation of plaque analysis in daily 
clinical routine require definition, standardization and further validation. 
 
Given CCTA provides a tri-dimensional dataset of the heart and coronary 
vessels, CCTA allows the assessment of the entire arterial wall, including the 
visualisation of the atherosclerotic plaque (244). This allows detection of 
CAD at early stages, assessment of total atherosclerotic plaque burden and 
plaque characterisation (244). It is well known that heart attacks may occur 
in a site of non-obstructive – but ‘vulnerable’ - plaque (245). In the context of 
CAD diagnosis and risk stratification, exercise testing or pharmacologic 
cardiac imaging (e.g. MPS) are sensitive to ischaemia secondary to high-grade 
coronary stenosis (160). For this reason, detection of preclinical coronary 
atherosclerosis may result in beneficial lifestyle modification, and may as 
well provide the rationale for initiation of preventive medical therapy. 
 
At present however, there is limited evidence regarding the usefulness of 
CCTA in asymptomatic patients. For this reason, as well as the issue of 
radiation exposure and costs of imaging, CCTA is not recommended as a 
screening test in the general, unselected asymptomatic population (183, 
246). 
 
4.4   Limitations of CCTA 
Several factors should be considered prior to referring a patient to CCTA in 
order to identify possible contraindications. Patients unable to cooperate 
with breathing instructions (who cannot hold breath for ~10 seconds) or 
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patients unable to lie down flat are unlikely to be imaged successfully with 
CCTA. 
Contraindications to iodinated contrast use include prior/severe 
anaphylactic contrast reaction or renal insufficiency (but end-stage renal 
disease is not an absolute contraindication) for contrast induced 
nephropathy (refer to section 4.6) (247). 
Contraindications for beta-blockers include severe chronic obstructive 
pulmonary disease, severe asthma, decompensated heart failure and 
advanced atrioventricular block.  
Contraindications for sublingual nitroglycerin are severe aortic stenosis, 
hypertrophic cardiomyopathy and recent use of phosphodiesterase-5 
inhibitor. 
The presence of metallic pacemakers/intracardiac defibrillator leads, stents 
and mechanical prosthetic valves can produce beam-hardening and streaking 
artefacts over adjacent coronary arteries (183), however, these devices do 
not pose a contraindication to CCTA. High BMI (>40) can lead to decreased 
image quality unless scan parameters are optimised (X-ray tube kilovoltage, 
tube current, patient preparation and instructions, image reconstruction 
techniques), however, an elevated BMI however is not a contraindication to 
CCTA. 
Motion artefacts can also occur particularly in patients with elevated heart 
rate and can result in degraded image quality. The presence of heavily 
calcified coronary plaques is one of the leading causes of misjudging lumen 
narrowing. This happens because calcifications can obscure the contrast-
filled lumen, resulting most frequently in overestimation of stenosis degree 
(248). Adjusting the window level, using appropriate reconstruction kernels 
and post processing settings (e.g. thin-slice display) can help in visualising 
the lumen in calcified segments (249-251). 
 
4.5   CCTA in ESRD 
Limited data are available regarding the use of CCTA in the ESRD population 
(252-256). It has been reported that CCTA is feasible and safe to exclude 
major epicardial CAD in the asymptomatic ESRD disease population(252). 
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However, a further concern in the ESRD population is the contrast-related 
volume overload. Published data suggest that as a precaution it is safer to 
perform the CCTA as close as possible to the next dialysis session(253). More 
importantly, with a low amount of iodinated contrast volume (average 67ml), 
Jug and colleagues did not observe any significant volume overload in their 
study(253). In the study by Mao et al.(252), CCTA was very well tolerated 
and there was no increased 30-day adverse event rate including death, MI, 
congestive heart failure or any other reaction that can be attributed to the 
CCTA procedure. 
CCTA in combination with CAC score has been found to be very useful in 
predicting cardiovascular events in the ESRD population. Patients with 
presence of both coronary artery calcifications and coronary artery stenosis 
detected on the CCTA had a higher risk of cardiovascular complications 
compared to those without any of them(253).  
In the studies by Jug et al. and Park et al.(253, 254), CCTA showed a high 
diagnostic accuracy at per-patient and per-vessel level (using invasive 
coronary angiography as reference standard), suggesting that CCTA can be a 
reliable non-invasive imaging modality for guiding clinical management of 
ESRD patients. CCTA not only provided information about the coronary 
arteries but could also identify and quantify LV dysfunction (when 
retrospectively ECG-gated), which could be valuable additional information 
when trying to identify high-risk patients(253). 
As in the normal population, high coronary calcium can affect the diagnostic 
accuracy of CCTA in this population(254). Surprisingly, however, in the few 
studies published, even in the presence of high calcium scores CCTA was very 
helpful in the exclusion of significant coronary artery disease(252, 253). 
More recently Winther et al (256) analysed the diagnostic performance of 
CCTA in ESRD patients awaiting kidney transplant and they suggested that 
CCTA can play a key role in this population. All patients included in this study 
(n:138) underwent CCTA, MPS and invasive coronary angiogram and CCTA 
was found to have high sensitivity and NPV to diagnose coronary stenosis but 
not surprisingly it was associated with a high number of  false-positive 
results (reduced specificity due to high coronary calcified plaque burden). 
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MPS sensitivity was found to be low (and this is in line with the already 
published data) and the authors suggested that this test could not be used as 
a first-line modality but it could have a role as a second-line test in presence 
of positive CCTA (especially in the presence of high calcium) by increasing 
the PPV and reducing the need for invasive coronary angiography - albeit at 
the cost of lower sensitivity. 
Overall, the available data seem to suggest that CCTA can be considered a 
useful tool to rule out significant atherosclerotic CAD in the ESRD population, 
and it can be used as an initial diagnostic test to identify patients that do not 
need further testing (253, 254, 256)(Table 4). 
 
 
Table 4: Diagnostic performance of CCTA in renal patients. 










2015 Winther et 
al.(256) 
ICA Stenosis 93 63 41 97 
2013 Jug et al.(253) ICA Stenosis 100 78 92 100 
2011 Park et al.(254) ICA Stenosis 93 80 81 93 
Sens: sensitivity. Spec: specificity. ICA: invasive coronary angiography. PPV: positive 
predictive value. NPV: negative predictive value. Stenosis parameter defined as >50% 
diameter reduction detected on CCTA. 
 
 
4.6   Contrast Induced Nephropathy 
Contrast-induced nephropathy (CIN) is an important complication of the use 
of iodinated contrast agent and it can be associated with an increased 
morbidity, including the need for short/long-term dialysis or renal 
transplantation (257). 
Three components define CIN (258): 
1) Absolute or relative increase in serum creatinine compared to the baseline 
values (increase of 25% or more, or an absolute increase of 0.5 mg/dl or 
more 
in serum creatinine from baseline value, at 48–72 h following the exposure to 
iodinated contrast media). 
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2) Temporal relationship between the rise in serum creatinine and exposure 
to the iodinated contrast media. In particular, the first 24 h post-exposure are 
crucial in the development of CIN, in fact in 80% of patients who develop CIN, 
the serum creatinine rise was seen within the first 24 h post-exposure, and 
nearly all patients who developed serious renal failure had a rise in serum 
creatinine within this time frame (259). 
3) Absence of other explanations for renal impairment (e.g. cholesterol 
embolism).  
The risk of developing CIN is low in the normal population with preserved 
renal function (risk of 2%) but increases up to 12% to 27% in CKD 
population (260) and can go up to 50% in patients with concomitant CKD 
and diabetes (261). 
Although most episodes of CIN are self-limiting and tend to resolve within 10 
days (262), even a small persistent increased creatinine is associated with 
increased mortality (263).  The risk of CIN can be significantly reduced by 
using a lower volume of contrast media (<100ml) with a potentially 
rewarding outcome. It is important to mention that patients on dialysis 
usually have some degree of residual renal function which contributes to the 
overall health and well-being of this population (264) and the use of iodinate 

















Chapter 5: Nuclear Medicine and Echocardiography  
 
5.1    Myocardial Perfusion Scintigraphy  
Nuclear medicine uses radionuclides which have unstable nuclei (having an 
exceeding neutron) and decay until  become stable. During this process there 
is emission of beta and gamma radiation which are used for nuclear imaging. 
The most commonly used radionuclide for MPS is technetium-99m. This 
atom has satisfactory gamma energy thus allows for good spatial resolution, 
has a short half-life (6h) and pure gamma emission. Technetium-99m 
(99mTc) is labeled with sestamibi or tetrofosmin for cardiac perfusion 
imaging (265). 
The radiopharmaceutical is usually administered to the patient via 
intravenous injection and ideally it concentrates in the target organ; the 
gamma rays produced are detected by a gamma camera in order to produce 
an image, which results from the radionuclide distribution. The gamma 
camera has a multi-hole collimator, which has the role of reducing the 
background gamma radiation that can come from the patient but also from 
other sources in the room. After passing through the collimator, the gamma 
rays reach a large crystal (usually made of sodium iodide), which will absorb 
them generating a flash of light. The light is then absorbed by 
photomultipliers, which converts light into photoelectrons, which are then 
analyzed to produce images (265).  
It is possible to study the dynamics of some organs; in particular, for heart 
function, separate images  (of 40ms) are acquired at 20-30 different 
moments of the cardiac circle in order to image multiple moment of the 
cardiac circle. This allows calculation of the cardiac function and videos can 
also be generated (265). 
The planar gamma cameras described above has the main limitation that it 
produces superimposed images. This can be addressed using the tomography 
technique with two methods: SPECT (single-photon emission computed 
tomography) and PET (positron emission tomography)(265). 
SPECT imaging uses a gamma camera with a parallel hole collimator rotating 
around the patient who lies on a bed. With this technique several parallel 
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transverse image sections are imaged and also sagittal, coronal and oblique 
images can be generated as well as videos. Gating is also possible for cardiac 
studies in order to obtain information about cardiac function and perfusion 
(265). 
One of the main problems of this technique is the attenuation of the photons 
within the body due to Compton scattering, which refers to the change in 
direction of the photons while they travel thought different body tissues and, 
as result, they are not detected by the gamma camera (266). As a 
consequence, reconstructed images would show a reduced activity in the 
centre of the source due to these missed counts. Using an algorithm for 
gamma attenuations when images are reconstructed solves this problem. 
More recently, new and more advanced SPECT scanner have been developed 
which use semiconductors which, in response to gamma photons, combine 
the function of scintillation crystal and photomultiplier tubes by producing 
directly electron current. The vast majority of these scanners have a 
Cadmium-Zinc-Telluride (CZT) detector that operates at room temperature 
and has high-energy resolution and very high-count rate (267). This 
technology is called Solid state SPECT, enabling shorter imaging protocols 
with reduced injected doses of radio-isotopes and patient exposure (268). 
 
5.2  Radiation Dose Reduction in MPS.  
In the last decades there has been significant reduction in radiation dose for 
MPS. The main techniques used to reduce radiation dose are (269, 270): 
-Radiotracer selection: radiation dose is directly related to the half-life of the 
radiotracer and dose of radiotracer administered. Usually 99mTc agents are 
more used than thallium 201 (201Tl) due to their shorter half-life, lower 
effective dose, and superior image quality. The radiotracer dose is also 
adjusted according to patien’s BMI with a significant reduction in radiation 
dose which has been reported to be as much as 58% for patients and 50% for 
staff (271). 
-Stress first or Stress-only technique: in this approach, the patient undergoes 
stress imaging first and if this is normal then there is no need for rest 
imaging. A stress test is considered normal when there is homogenous 
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myocardial perfusion, normal ejection fraction and normal left ventricle 
volumes during maximal stress and no ECG changes suggesting ischemia 
(272). If the rest scan is avoided the radiation exposure for the patient is 30% 
less and there is also a 40% dose reduction for the staff (273) 
-Advantages in technology: significant technical progress has been made in 
recent years  resulting into remarkable dose reduction. New iterative 
reconstruction methods with noise reduction and resolution recovery 
significantly increase image quality, allowing studies with half- and quarter-
dose radiotracer protocols (274). 
New solid-state SPECT scanners have significant increase in count sensitivity 
(275-277).  These developments enable low-dose and ultra- low-dose MPS, 
with radiation doses which can be as low as 2mSv (270) 
 
5.3    Positron Emission Tomography (PET) (178). 
One of the commonest PET imaging radionuclides is 18-fluorine (18F). This 
emits positive beta particles, which travel for approximately 2mm within the 
body before being annihilated by an electron. This produces two energetic 
photons, which are generated at the same time in almost opposite direction. 
PET technique is based on the detection and localization of these two 
photons. The PET scanner has a ring of detectors around the patient, which 
detects the photons to create images. Nowadays integrated PET-CT systems 
are used. CT and PET are mounted on the same support next to each other 
and once the CT images are acquired, PET images of the same section are 
subsequently collected. This technique allows almost perfect matching 
between the functional and anatomical images(178).   
Cardiac PET has several applications and uses several tracers:  
Fludeoxyglucose 18F (18F-FDG) PET imaging is used for viability studies and 
it has been reported to have an average sensitivity and specificity around 
90% for the detection of angiographically significant CAD and a very high 
accuracy for the prognosis of patients with suspected or known CAD (278). 
PET myocardial perfusion imaging can be performed with different tracers 
such as oxygen-15 water, N-13 ammonia and 82-Rubidium. Myocardial 
uptake depends on the tracer extraction from the blood and the tracer 
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delivery and differences in the first-pass extraction influences the myocardial 
uptake in relation to the blood flow (279). The uptake can be passive (free 
diffusion) or can happen with active first pass extraction through the 
sodium–potassium exchange transporter (NA+/ K+ ATPase) (280). 
Oxygen-15 water (O-15 H2O) has a linear uptake and free diffusion, hence it  
correlates perfectly with the myocardial blood flow.  The short half-life of 2.4 
minutes allows measurements to be repeated at short intervals of 10 to 15 
minutes.  
N-13 ammonia has non-linear uptake, both free diffusion and active first pass 
extraction. It has a half-life of 10 minutes which allows repeated evaluations 
of rest and stress myocardial blood flow at longer time intervals (about 30-
40 minutes) when compared to O-15 H2O. Assessment of stress perfusion 
and left ventricular function is also possible 
82-Rubidium (Rb-82) has non-linear uptake and active first pass extraction. 
It has an ultra-short half-life of approximately 1.3 minutes which permits 
serial imaging during both rest and stress. 
 
The literature reports higher sensitivity and specificity for PET compared to 
SPECT for the detection of CAD. Importantly, quantitative measurements of 
myocardial perfusion can play a pivotal role in the detection of balanced 
ischaemia (281). Quantitative imaging with SPECT, on the other hand, is also 
becoming available. 
- 18F-FDG PET is also used in cardiology for other conditions, for instance for 
the detection of inflammatory and infectious conditions (e.g. endocarditis 
and sarcoidosis) and atherosclerosis(281).  
 
5.4    Echocardiography. 
Echocardiography is a well-established non-invasive technique which uses 
ultrasounds waves to produce images. Ultrasound waves are produced by a 
piezoceramic transducer, which generates an ultrasound beam from an 
electrical signal. The ultrasound beam will be reflected in different way from 
the different internal organs and return to the probe with different 
echocardiography return, which is affected by the tissue composition and 
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depth. Computed analysis of the transmitted and received signals allows real 
time anatomical evaluation of the scanned body section(178). 
Two-dimensional, three-dimensional, and Doppler ultrasound images are 
used for the evaluation of the heart. This technique provides information 
about cardiac function and morphology as well as hemodynamic information 
if performed during stress (178). 
Doppler technique is used for the assessment of the cardiac flows, to study 
abnormal shunts and valvular pathologies such as regurgitation and stenosis. 
The stress technique is a combination of 2D echocardiography with either 
pharmacological or physical stress. The stress will increase the myocardial 
oxygen need and  territories supplied by arteries with hemodinamically 
significant CAD will show a worsening in the wall motion (282). 
Given that echocardiography is widely available, non-invasive and radiation 
free, it is routinely performed in ESRD patients as part of their normal 
cardiac screening. echocardiography plays a big role in this population in fact 
can provide several important information: 
-Evaluation of LVH: as previously described LVH is a common complication in 
this population and this technique can provide excellent evaluation of the left 
ventricular volumes and mass with high accuracy for the detection of LVH 
and the assessment of its geometry (concentric or eccentric) (283). 
-Evaluation of left ventricular systolic dysfunction: the prevalence of the LV 
systolic dysfunction has been reported to be as high as 28% ESRD population 
(284) and it is an important unfavorable prognostic indicator (285). The 
echocardiography evaluation of the LV systolic function is performed with 
methods that evaluate the degree shortening and ejection fraction. 
-Evaluation of left ventricular diastolic dysfunction: diastolic dysfunction is 
characterized by abnormal LV compliance and relaxation, which leads to an 
increase in the filling pressures. An increase of the LV volume can complicate 
into acute pulmonary edema and intradialytic hypotension  (286, 287) even 
in presence of normal EF hence it is crucial to identify these abnormalities in 
early stages. 
-Evaluation or left atrial dilatation: left atrium dilatation is a strong predictor 
of cardiovascular events in the general population (288) such as atrial 
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fibrillation, cerebrovascular accident, heart failure, myocardial infarction and 
cardiac death (289).  In the ESRD population it has been demonstrated that 
the atrial dilatation was an independent predictor of mortality in patents on 
dialysis (290, 291). The assessment of the LA with echocardiography should 
be done in two-dimensional mode and not by the traditional measurement of 
the anteroposterior diameter in the M-mode (292, 293).  
-Assessment of pericardial disease: Acute pericarditis is a possible 
complication in ESRD patients and it can be caused by uraemia and/or 
inadequate dialysis (294). Sometimes drainage is necessary to avoid cardiac 
tamponade and echocardiography can play an important role in the diagnosis 
and invasive treatment of this condition. 
-Stress Echocardiography: pharmacological stress echocardiography allows 
the assessment of myocardial ischemia and provides at the same time 
information about the cardiac function.  The presence and extension of the 
ischemia are independent prognostic values in this population (295)making 
this technique very appealing also for this group of patients. 
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Chapter 6: Project Methods 
 
6.1    Study Population, Inclusion and Exclusion Criteria for the Project 
The ACHILLES study (REC Ref. 12/LO/0672) was directly supported by the 
NIHR Cardiovascular Biomedical Research Unit at Barts (Grant no. 
MCPH1B9T/24ET52), which is supported and funded by the National 
Institute for Health Research (NIHR). 
 
The primary hypothesis was that CCTA could perform at least as well as MPS 
in the cardiovascular assessment of this patient population. 
 
The study protocol received Research Ethics Committee approval and all 
patients gave written informed consent. My involvement in the study 
consisted in approaching patients, inform them and obtain consent. I was 
then in charge of organising the CT scanning slots and supervising the scan 
acquisition. For patient recruitment, I attended the Transplant Assessment 
Clinic of the Royal London Hospital between October 2012 and March 2014. 
Patients considered suitable for kidney transplantation were invited to take 
part in this research study and an information leaflet was given to them. 
After 3-4 days I would call the patient to discuss again the study, answer their 
questions, and if they agreed to join the study, I would plan the CCTA in the 
best day for them, taking into account the dialysis sessions . Exclusion criteria 
were <18 years of age, known allergy to iodine, unstable clinical condition 
(haemodynamic or electrical instability), severe systemic illness (e.g. cancer), 
inability to lie flat and hold the breath for 10 seconds, failure to provide 
informed consent. 
Data on patient symptoms and cardiovascular risk factors were collected 
prospectively using specific patient questionnaires and were checked with 
the electronic patient records. Hypertension was defined as having blood 
pressures higher than 140/90 mmHg or being on treatment for 
hypertension. Hyperlipidaemia was defined as total cholesterol level of more 
than 200 mg/dL (5.17 mmol/L). Diabetes was defined as recurrent or 
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persistent high blood sugar above normal levels [Fasting plasma glucose 
level ≥ 7.0 mmol/l (126 mg/dl); Plasma glucose ≥ 11.1 mmol/l (200 mg/dl) 
two hours after a 75 g oral glucose load; glycated haemoglobin (HbA1C) ≥ 48 
mmol/mol] Participants were considered to have hypertension, 
hyperlipidaemia and diabetes if this was recorded in the medical records and 
if they were on treatment for any of these conditions. 
Participants were considered to have family history of cardiovascular disease 
according to the British Heart Foundation definition (www.bhf.org.uk), if : 
 Father or brother was/is diagnosed with cardiovascular disease under 
the age of 55. 
 Mother or sister was/is diagnosed with cardiovascular disease under 
the age of 65. 
Chest pain was defined as follow (296): 
Typical chest pain: Meets three of the following characteristics: 
1. Substernal chest pain of characteristic quality and duration (usually 
located near the sternum, or from the epigastrium to the lower jaw or 
teeth, between the shoulder blades or in either arms and it is 
described as pressure, heaviness sometimes strangling, constricting, 
or burning). 
2. Provoked by exertion or emotional stress 
3. Relieved by rest and/or nitroglycerine (usually lasting less than 
10min) 
Atypical chest pain meets two of the characteristics described above. 
Non-anginal chest pain meets one or none of the characteristics described 
above. 
 
Patients underwent CCTA (research) as well as MPS (standard of care). 
Clinical management was based on standard of care investigations (MPS and 
conventional coronary angiography (CCA), if performed), but it was not 
mandated by CCTA findings. 
Results were reported according to the STARD (297) criteria (Standards for 
Reporting Diagnostic accuracy studies). 
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6.2    CAC Score and CCTA Protocols 
The CT scans were performed at the London Chest Hospital using a 128-slice 
second-generation dual-source CT system (Somatom Definition Flash, 
Siemens Healthcare, Forchheim, Germany) (Scanner’s technical feature 
summarized in table 5; Advantages of dual source technique are discussed in 
Chapter 4). 
 
          Table 5: Technical features of Somatom Definition Flash. 
X-Ray tube 2 x VectronTM 
Detector 2 x StellarInfinity detector with 3D anti-
scattering. 
Each StellarInfinity has 96 detector raws. 
Number of slices 
acquired/rotation 
384 (2 x 192) 
Rotation time Up to 0.25 s 
Temporal resolution 66 ms 
Generator power  240 kW (2 x 120 kW) 
 kV Steps 70,80.100.120.140 kV 
Spatial resolution 0.22 lp/cm (0.24 mm) 
Max. scan speed 737 mm/s with Turbo Flash 
Table load Up to 307 kg / 676 Ibs 
Gantry opening 78 cm 
Imaging 
reconstruction 
Iteractive reconstructions (ADMIRE) 
 Filtered back projection (FBP) 
 
 
Wherever possible for patients on dialysis treatment we scheduled the CT 
appointment on the same day prior to the dialysis session, or the day before.  
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CCTA images were evaluated by an experience consultant who was unaware 
of  the MPS findings.  
Patients were instructed to follow the breathing instructions and were 
rehearsed to hold their breath for approximately 10-12 s before the scan 
procedure.  
 
Patients with a heart rate >65bpm and without contraindications to beta-
blockers (contraindications are: asthma, bradycardia, second or third degree 
heart block) received 5-35mg of intravenous metoprolol in order to achieve a 
target heart rate of <65beats/min. Sublingual nitrates were used in patients 
without contraindications (contraindications are: severe aortic stenosis, 
glaucoma, low blood pressure, severe bradycardia and the use of 
phosphodiesterase inhibitors in the last 24-48h). 
 
First, all patients underwent a non-contrast scan for the calculation of the 
CAC score using the Agatston method. A prospectively ECG-triggered, high-
pitch spiral protocol was used. Scan parameters were an X-ray tube voltage 
of 120kV and a tube current of 75mA.  
 
For CCTA, either a prospectively ECG-triggered or a retrospectively ECG-
gated protocols were used, depending on the presence of heart rate 
irregularities immediately prior to the scan. Both X-ray tubes were operated 
at a voltage of 100 kV. Scout-based automatic tube current modulation 
(CareDose 4D, Siemens Healthcare, Forcheim, Germany) was used with the 
reference tube current–time product set at 370 mAs per rotation. 0.75mm-
thick images were reconstructed with a slice increment of 0.5mm. 
 
A volume of 50ml of contrast agent (300 mg/mL, Omnipaque, GE Healthcare, 
Milwaukee, MI) was injected with an injection rate of 5mL/s into an 
antecubital vein through a 20-gauge catheter, using a dual-head power 
injector (Stellant, Medrad, Indianola, USA). Contrast was followed by 40ml of 
saline with the same injection rate. 
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A test bolus scan of 10ml of contrast (followed by 30ml of saline) was 
injected to determine the time to peak enhancement in the ascending aorta. 
Attenuation changes in the ascending aorta were monitored with low-dose 
single slice scans obtained at 1s time intervals. The time to peak 
enhancement, summed to a fixed delay of 3s, was applied as the diagnostic 
delay to initiate the CCTA acquisition. Scans were performed in a 
craniocaudal direction, starting below the aortic arch and ending just below 
the base of the heart. 
6.3 Image Reconstruction 
CAC score images were reconstructed with a slice thickness of 3 mm, an 
increment of 1.5 mm, a field of view of 180 mm and a medium-soft 
convolution kernel (B35). CCTA images were reconstructed with a slice 
thickness of 0.75 mm, an increment of 0.5 mm, a field of view of 180 mm, a 
medium-soft convolution kernel (B26) and additionally a dedicated sharp 
convolution kernel (B46) in patients with detectable coronary calcium. 
6.4    Image Analysis 
CAC scores were obtained according to standard procedure using 
commercially available software (syngo Calcium score, Siemens Healthcare). 
The Agatston score was calculated according to the method described in 3.2. 
Agatston CAC score results were dichotomised as zero CAC score (Agatston 
CAC score =0) and positive CAC score (Agatston CAC score >=1). A sub-
analysis was conducted in patients with high CAC score (using a threshold of 
1000), because heavy diffuse calcifications in the coronary arteries are a 
known potential challenge to the accurate interpretation of CCTA. 
CCTA axial images, multiplanar reformations, and maximum intensity 
projections were used to evaluate the coronary arteries. Coronary artery 
segments were classified according to a modified American Heart Association 
17-segment model (298). Datasets were evaluated by two independent 
observers (one with 3 years’ experience, one with 10 years’ experience). 
Disagreement was resolved by consensus reading. The severity of coronary 
artery stenosis was visually assessed using a grading system recommended 
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by the Society of Cardiovascular Computed Tomography (244) (Table 6). A 
threshold of ≥50% coronary diameter reduction was used to define 
significant stenosis/obstructive CAD. Presence of at least one ≥50% coronary 




Table 6 modified from (244). Qualitative coronary artery stenosis grading.
 
Myocardial wall thickness was measured in all study participants at the level 
of the basal septum, using multiplanar reformation short-axis views of the 
left ventricle at basal level. A mid-to-end diastolic CT dataset was used. LVH 
was defined as thickness ≥13 mm, in keeping with echocardiography criteria 
by the British Society of Echocardiography (299) (Table 7). 
Table 7: Modified from (299). Reference limits and values of left ventricular wall 
thickness. 
 Normal Mild  Moderate  Severe 
LV Wall Thickness (mm) 6-12 13-15 16-19 ≥20 
Descriptive Lumen Obstruction Stenosis Grading 
Normal  Absence of plaque/no luminal narrowing 
Minimal Plaque with <25% diameter narrowing 
Mild 25%–49% diameter narrowing 
Moderate 50-69% diameter stenosis 
Severe 70%–99% diameter stenosis  
Occluded 100% diameter stenosis 
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6.5    Radiation Dose Estimates 
To provide estimates of the effective radiation dose associated with CT, the 
dose-length product (DLP) for each scan was multiplied by a 0.014 
conversion factor for the chest (300). 
 
6.6    Myocardial Perfusion Scintigraphy (MPS) Protocol 
The MPS studies (standard of care) were performed at the Royal London 
Hospital using a two days stress first technique. For stress images, adenosine 
was infused at a dose of 140mcg/kg/min for 6 minutes. Based on the 
patient’s body weight, 250-350 MBq of Tc-99m tetrofosmin/sestamibi were 
injected 4 minutes into the adenosine infusion. Image acquisition started 
within 2 hours (ECG-gating, 16 frames/cardiac circle). For the resting images, 
750-1000 MBq of Tc-99m tetrafosmin/sestamibi were injected and images 
were acquired using the same protocol. 
 
6.7 MPS image analysis 
Images acquired on both gamma cameras are automatically transferred to 
the workstation for processing and image analysis. MPS were reported by an 
experienced consultant who was not aware of the CCTA findings. 
MPS was defined as positive when a perfusion defect was identified. A 
perfusion defect detected on a region that it is normal on the rest images was 
considered suggestive of myocardial ischaemia. Perfusion defect on both 
stress and rest images was considered as myocardial infarction.  
All images were evaluated by using a 17-segment model in order to match 
coronary vessels and myocardial territories.  
 
6.8    Statistical analysis 
Statistical analyses were performed using commercially available software 
(SPSS, version 20.0, Chicago, IL, USA). Continuous variables are presented as 
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mean±SD or median with interquartile range when not normally distributed. 
The Kolmogoroff-Smirnow test was used to test for normality. Categorical 
variables are presented as frequencies and percentages and compared using 
the χ2 test. 
Cigarette smoking was recorded as positive if patients were current smokers. 
Diagnostic performance of CAC score and CCTA compared to MPS was 
evaluated on a per-patient and per-vessel levels and expressed as sensitivity, 
specificity, positive and negative predictive values, and their corresponding 
95% confidence intervals. 
The agreement between CCTA and MPS in assessing the presence of LVH was 
calculated by means of Cohen’s kappa statistics. Kappa results for agreement 
were interpreted as being poor (κ < 0.20), fair (κ = 0.21–0.40), moderate (κ = 
0.41–0.60), good (κ = 0.61–0.80), very good (κ = 0.81–0.90), or excellent 
(κ≥0.91). A P-value of less than 0.05 was considered significant.  
Since this was a feasibility study and part of a clinical development 
programme, formal sample size calculation was not performed. The 
population sample was established the basis of the expected number of 












Chapter 7: Diagnostic Performance of CAC Score in Predicting MPS 
Perfusion Defects 
7.1 Rationale and Aim 
The rationale for studying CAC score was introduced in paragraph 3.4. In the 
ESRD population, CAC score is not a highly specific indicator of 
atherosclerosis, because medial sclerosis – that is not due to atherosclerosis 
but is a manifestation associated with uraemia - contributes to total CAC 
score. Thus in ESRD patients both intimal calcifications related to 
atherosclerosis and medial calcification related to uraemia will contribute to 
total CAC score. Both changes can potentially lead to perfusion defects on 
MPS. Both intimal and medial calcification may also be associated with 
cardiovascular death and all cause death, although this does not always imply 
the presence of underlying obstructive luminal CAD (171-174). A baseline 
zero CAC score is associated with a significant lower rate of cardiovascular 
events in the ESRD population (113). Hence, zero CAC score is a simple and 
practical tool to exclude both atherosclerosis and medial sclerosis in the 
coronary arteries. 
 
The first aim of this thesis (Aim 1) was to evaluate the diagnostic 
performance of CAC score in predicting MPS perfusion defects as the 




From October 2012 to March 2014, patients were prospectively enrolled 
among those referred for cardiovascular screening at the Transplant 
Assessment Clinic of the Royal London Hospital. The study population, 
inclusion and exclusion criteria are described in section 6.1. 
 
7.2.2 CAC Score and MPS Protocols 
CAC score and MPS were performed in all participants according to the 
protocols described in section 5.2 (CAC score) and 5.6 (MPS). 
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7.2.3 Statistical Analysis 
As described in 5.8, statistical analyses were performed using commercially 
available software (SPSS, version 20.0, Chicago, IL, USA). The diagnostic 
performance of CAC score compared to MPS was evaluated on a per-patient 
and per-vessel level and expressed as sensitivity, specificity, positive and 




7.3.1 Baseline Characteristics 
A total of 119 participants received CAC score and MPS. The inclusion 
procedure of the whole study is detailed in Figure 6. 
 















Calcium score and 
MPS 
N=119 
• Did not attend MPS N=12 
Population with 
Calcium score, 
CCTA and MPS 
N=102 
• Declined administration of 
iodinated contrast: N=12  






Baseline clinical characteristics of the 119 participants that underwent CAC 
score and MPS are shown in the Table 8. 
 
Table 8. Baseline clinical characteristics of 119 patients who underwent CAC score 
and MPS.  
 
BMI = body mass index; CAD = coronary artery disease  
 
The data were positively skewed (Kolmogorov–Smirnov test p<0.01; 
Shapiro–Wilk test p<0.01) and the median of the calcium score was 75 (0-
396), range 0-4603. 
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The average DLP for calcium score was 26.25 (+/- 9.8). 
 
7.3.2. CAC Score and MPS Perfusion Defects 
The median (IQR) CAC score was 53 (0-294) in patients without MPS 
perfusion defects, and 171 (17-1007) in patients with perfusion defects 
(p=0.046 from Mann-Whitney test).Among the 119 participants that 
underwent CAC Score and MPS, 36/119 (30%) participants had a zero-CAC 
score, of whom 33/36 (92%) had no perfusion defects on MPS. Eighty-
three/119 (70%) participants had CAC score >1, of whom 60/83 (72%) had 
no perfusion defects on MPS (Table 9). 
Only 3 participants with zero CAC score had perfusion defect noted on MPS. 
These 3 participants went on to have CCTA and were found to have moderate 
LVH without coronary artery plaque on CCTA (Chapter 8). 
 
 
Table 9: Cross-Tabulation of CAC score vs MPS 
 MPS Negative MPS Positive Total
CAC Negative 33 (92%) 3 (8%) 36
CAC Positive 60 (72%) 23 (28%) 83
Total 93 (78%) 26 (22%) 119  
CAC Score positive is defines as total CAC Score ≥1; MPS 
Positive is defined as presence of perfusion defects of MPS. 
 
 
The sensitivity, specificity, PPV and NPV of CAC score in predicting MPS 
perfusion defects were 88% (CI: 70-97), 35% (CI: 26-46), 28% (CI: 18-39) 









7.4 Discussion and limitations 
The main findings of our study were as follows: 
 
Firstly, only approximately one in five (22%) ESRD patient awaiting a kidney 
transplant were found to have perfusion defects on MPS. Overall this finding 
was in agreement with the clinical estimation of the pre-test probability of 
CAD, which was low. This suggests that the use of a non-invasive test instead 
of an invasive test appears justified. 
 
Secondly, we found that approximately a third (32%) of the patients had zero 
CAC score. This finding implies the absence of coronary atherosclerosis as 
well as the absence of medial sclerosis, and is known to be associated with 
good prognosis. 
 
CAC score has been extensively validated as a powerful non-invasive imaging 
modality in the general population. Even in presence of diabetes, a zero CAC 
score translates into a similar cardiovascular risk to patients without 
diabetes (158). 
 
In all but three patients, there was agreement between CAC score being zero 
and MPS being negative for perfusion defects. When CAC score was 
dichotomised into zero vs. >=1, sensitivity (88%) and NPV (92%) were high, 
despite lower specificity (35%) and PPV (28%). CAC score is a rapid non-
expensive, contrast free and low-radiation dose test. The high NPV found in 
the low likelihood population included in this study suggests that zero CAC 
score may be a useful clinical tool in the pre-surgical screening of ESRD 
population, particularly by identifying patients in whom further testing for 
significant CAD is not required.  
 
Few promising data were published so far regarding CAC score in the ESRD 
population showing that CAC score was a good predictor of future coronary 
events and more importantly a zero CAC score translated into a significantly 
lower cardiac event rate (113) (discussed in Chapter 3). 
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We also found that approximately two thirds (68%) of the patients included 
in this study had CAC score ≥1, but only one fifth had MPS perfusion defects. 
This suggests that CAC score ≥1 is not reliable to rule-in MPS perfusion 
defects, no matter if they are the result of atherosclerosis, uraemic changes 
or both. 
 
CAC score has a further limitation. MPS perfusion defects can result from 
atherosclerosis, uraemia but also LVH can play a role. As CAC score is a 
contrast free technique, LVH cannot be assessed reliably due to very poor or 
absent differentiation between blood pool and myocardium in baseline 
conditions. 
 
CAC is also limited because it is not a specific test to discriminate between 
the two different pathophysiological processes such as uraemia and 
atherosclerosis, both leading to vascular calcifications. 
 
We could not demonstrate statistically significant differences in CAC score in 
patients with different baseline characteristics, such as for instance presence 
vs. absence of diabetes, hyperlipidaemia and cigarette smoking. Similarly, 
the, relationship between CAC score and dialysis duration did not reach 
statistical significance. Studying the effect of these variables on CAC score, 
however, was beyond the purpose of our study, which was not sufficiently 
powered for these analyses.  
 
Also, we have not studied imaging findings in relation with any circulating 
biomarkers. Of note, no circulating biomarkers are currently available for the 
reliable dectection of ischaemia in patients with stable CAD. 
 
A further limitation of this study was the lack of comparison with a reference 
standard. This was discussed with the clinical and research teams when 
designing this study, and it was felt it would have been unethical to perform 
invasive coronary angiogram in all patients for research purposes, even 
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when not clinically indicated, due to the risks associated with intra-arterial 
puncture and contrast injection. 
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Chapter 8: Diagnostic Performance of CCTA in Predicting MPS Perfusion 
Defects 
 
8.1 Rationale and Aim 
CCTA is an established non-invasive test to assess CAD. The strength of CCTA 
lays in its high negative predictive value (234) i.e. the excellent ability to rule 
out the presence of obstructive CAD. This applies to both stable chest pain 
patients and low-risk patients with suspected acute coronary 
syndromes(183). 
Promising but little data have been published regarding the use of CCTA in 
the ESRD population. The stigma that ESRD patients have heavily calcified 
coronary arteries has limited the research and clinical applications of CCTA 
in these patients. Few studies, however, reported that CCTA was safe to 
perform in asymptomatic ESRD patients (174) and had encouraging 
diagnostic performance, both at a patient and vessel level (301, 302). Data 
reported in this thesis (Chapter 6) showed that approximately one in three 
ESRD patients did not have any coronary calcifications.  
 
Given the aforementioned limitations of CAC scoring in ESRD patients, 
particularly the notion that vessel calcification can be the result of separate 
processes such as atherosclerosis and medial sclerosis, as well as the fact that 
perfusion defect may be secondary to uraemic changes and LVH and not only 
to epicardial coronary artery stenosis from CAD, we hypothesised that CCTA 
may be more helpful and accurate than CAC score to rule-out epicardial 
coronary stenosis from CAD, especially in patients with CAC score >=1.  
 
By providing anatomical imaging of the coronary arteries, CCTA should be 
capable of identifying those patients for whom revascularisation of CAD is 
potentially beneficial. CCTA can exclude CAD and be of reassurance for those 




Our finding that only one in five kidney transplant candidates had perfusion 
defects on MPS (Chapter 6) confirmed that a diagnostic tool of non-invasive 
nature was appropriate in this context, because the expected prevalence of 
perfusion defects in this population was rather low. 
 
The second aim of this thesis (Aim 2) was to evaluate the diagnostic 
performance of CCTA in detecting obstructive CAD as a predictor of MPS 
perfusion defects, with the latter as the standard of reference. 
 
8.2 Methods 
8.2.1 Population  
From October 2012 to March 2014, patients were prospectively enrolled 
among those referred for cardiovascular screening at the Transplant 
Assessment Clinic of the Royal London Hospital. Inclusion and exclusion 
criteria were discussed in section 5.1.  
We used a CAC score value of 1000 as a threshold to arbitrarily define 
patients with high coronary calcification. This widely accepted clinical 
threshold was used to divide the study population in patients with high 
(>1000) and low (between 1 and 1000) CAC score. We evaluated the 
performance of CCTA in predicting MPS perfusion defects in patients without 
any calcification i.e. zero CAC sore, with high and low CAC scores. 
 
8.2.2    CCTA and MPS Protocol 
CCTA and MPS were performed in all participants according to the protocol 
described in section 5.2 (CCTA) and 5.6 (MPS). 
8.2.3    Statistical Analysis 
The diagnostic performance of CCTA compared to MPS was evaluated at the 
patient and vessel level and expressed as sensitivity, specificity, positive and 
negative predictive values, and their corresponding 95% confidence 
intervals. The agreement between CCTA and echocardiography in assessing 
the presence of LVH was evaluated by calculation of Cohen’s kappa statistics, 




8.3.1 Baseline Characteristics 
A total of 102 participants underwent CCTA and MPS. Data on CAC score 
were also available in these patients (Inclusion procedure shown in 
Figure 6). The baseline characteristics of the 102 participants that 
underwent CCTA and MPS are shown in Table 10. 
 
Table 10: Baseline characteristics of 102 patients who underwent CCTA and MPS. 
 
BMI = body mass index; CAD = coronary artery disease 
 
Ninety/102 (88%) patients had echocardiography. LVH (defined 
according to the criteria of British Society of Echocardiography, as in 
section 5.4) was detected in 46% of the population (n=47/102). There 
was excellent agreement between CCTA and Echocardiography in 
identifying LVH (K=1; P=.000). 
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All but 1 patients among the 102 underwent CCTA with prospectively 
ECG-triggered protocol. Only one patient was scanned with 
retrospectively ECG-gated protocol due to an irregular heart rate. The 
average DLP for the whole population was 404 (+/- 170). 
 
 
8.3.2 Diagnostic Performance in the Entire Population 
No adverse events were recorded during or after CCTA. Among the 102 
participants who underwent CCTA and MPS, 79/102 (77%) participants had 
negative CCTA, of whom 69/79 (97%) had no perfusion defects on MPS. 
Twenty-three/102 (22%) participants had positive CTCA, of whom 13/23 
(56%) had perfusion defects on MPS (Table 11). 
Ten/79 (13%) participants with negative CTCA had perfusion defects noted 
on MPS. Of these patients, 7/10 (70%) had LVH. 
 
 
Table 11: Cross-Tabulation of CCTA vs MPS 
 
 MPS Negative MPS Positive Total
CCTA Negative 69 (87%) 10 (13%) 79 (78%)
CCTA Positive 10 (44%) 13 (56%) 23 (22%)
Total 79 (78%) 26 (22%) 102  
CCTA positive is defines as coronary artery narrowing ≥ 
50%; MPS Positive is defined as presence of perfusion 
defects of MPS. 
 
 
Overall the sensitivity, specificity, PPV and NPV of CCTA in predicting MPS 
perfusion defects at the patient level were 55% (CI: 35-77), 87% (CI: 78-94), 
57% (CI: 35-77) and 87% (CI: 78-94), respectively.  
The sensitivity, specificity, PPV and NPV of CCTA in predicting MPS perfusion 
defects at the vessel level were 48% (CI: 31-66), 92% (CI: 88-95), 41% (CI: 





8.3.3 Patients with Zero CAC Score 
Zero CAC score was found in 32/102 (31%) of the participants who 
underwent CTCA (Figure 7).  
 
 
Figure 7: *Sensitivity and PPV could not be calculated due to the small sample size 
 
In patients with zero CAC score, 31/32 (97%) had negative CCTA. In 
patients with zero CAC score, 28/32 (88%) had both negative CCTA and 
no perfusion defects on MPS. No participants with zero CAC score were 
found to have both positive CCTA and perfusion defects on MPS (Table 
12). Three patients with zero CAC score had perfusion defects on MPS 
(and negative CCTA). All of these three patients had moderate LVH, 
which was echocardiographically confirmed. 











Table 12: Cross-Tabulation of CCTA vs. MPS in the population 
with zero CAC Score 
 
 MPS Negative MPS Positive Total
CCTA Negative 28 (90%) 3 (10%) 31 (97%)
CCTA Positive 1 (100%) 0 (0%) 1 (3%)
Total 29 (91%) 3 (9%) 32  
CCTA positive is defines as coronary artery narrowing ≥ 
50% ; MPS positive is defined as presence of perfusion 
defects of MPS. 
 
The specificity and NPV of CCTA in predicting MPS perfusion defects at 
the patient level were 97% (CI: 82-99) and 90% (CI: 74-98), respectively.  
The specificity and NPV of CCTA in predicting MPS perfusion defects at 
the vessel level were 99% (CI: 94-100) and 97% (CI: 91-99), 
respectively. Sensitivity and PPV could not be calculated due to the small 
sample size. 
 
8.3.4 Patients with Positive CAC Score  
Positive CAC score (CAC score >=1) was found in 70/102 (69%) of the 
participants (Figure 7). In these patients, 22/70 (31%) had positive 
CCTA and 48/70 (69%) had a negative CCTA. Among the positive CTCA’s, 
13/22 (59%) had perfusion defects and 9/22 (41%) did not. Among the 
negative CTCA’s, 41/48 (85%) had no perfusion defects and 7/48 (15%) 
did. These 7 patients were found to have echocardiographically 
confirmed LVH. 
Only 13/70 (18%) patients had both positive CCTA and positive MPS. In 
41/70 (59%) patients, despite positive CAC score, CCTA and MPS were 








Table 13: Cross-Tabulation of CCTA vs MPS in the population 
with positive CAC score 
 
 MPS Negative MPS Positive Total
CCTA Negative 41 (85%) 7 (15%) 48 (69%)
CCTA Positive 9 (41%) 13 (59%) 22 (31%)
Total 50 (71%) 20 (29%) 70  
CCTA positive is defined as coronary artery narrowing ≥ 
50% ; MPS positive is defined as presence of perfusion 
defects of MPS. 
 
The sensitivity, specificity, PPV and NPV of CCTA in predicting MPS 
perfusion defects at the patient level were 65% (CI: 41-85), 82% (CI: 69-
92), 50% (CI: 36-79) and 85% (CI: 72-94) respectively.  
The sensitivity, specificity, PPV and NPV of CCTA in predicting MPS 
perfusion defects at the vessel level were 48% (CI: 31-67), 87% (CI: 81-
92), 40% (CI: 24-57) and 91% (CI: 85-95), respectively.  
 
8.3.5 Patients with High and Low CAC Score 
In patients with high CAC score (>1000; n=15), 5/15 (33%) had MPS 
perfusion defects (Figure 7). In these patients there was poor agreement 
between CCTA and MPS, with only 8/15 (53%) cases in agreement at the 
patient level. 
In patients with low CAC score (between 1 and 1000; n=55), 15/55 
(27%) had MPS perfusion defects. In these patients, however, agreement 









Table 14. Agreement between CCTA and MPS using CAC Score threshold value of 1000 
Total within group Both Positive Both Negative Total Agreement % agreement
CAC 1-1000 55 9 37 46 84%
CAC >1000 15 4 4 8 53%
Total 70 13 41 54  
 
Thirty-seven/55 patients (67%) of the participants with low CAC score 
and negative CCTA had no perfusion defect on the MPS. 
In 11/55 (20%) participants with a low CAC score there was 
disagreement between CCTA and MPS results. Particularly 3 participants 
had a positive CCTA and no perfusion defects on the MPS, of whom 2 had 
a coronary angiography that confirmed the CCTA findings. Both 
participants had two vessel disease on CCTA. Seven participants had 
perfusion defects on the MPS and no significant coronary stenosis 
detected on the CCTA; in 6 of these patients there was moderate or 
severe LVH. Three of these patients had a coronary angiography that 
confirmed the CCTA findings. 
Only 13 patients had coronary angiography .Coronary angiography was 
not systematically performed as part of the study protocol, as this was 
not deemed ethical and was not included in the study design.  
 
In patients with low CAC score, sensitivity, specificity, PPV and NPV of 
CCTA at the patient level were 60% (CI: 32-84), 93% (CI: 80-98), 75% 
(CI: 43-94) and 86% (CI: 72-95), respectively.  
The sensitivity, specificity, PPV and NPV of CCTA in predicting MPS 
perfusion defects at the vessel level were 53% (CI: 27-79), 91% (CI: 85-




8.4 Discussion and limitations 
The main findings of our study were as follows: 
 
Firstly, approximately one in five (23%) patients had perfusion defects on 
MPS. One in five patients had positive CCTA (23%). This confirmed the 
population had a low prevalence of coronary artery disease, hence the 
preference of non-invasive testing over invasive testing as a screening tool 
may be appropriate. 
 
We divided this population in groups according to the presence of coronary 
calcium detected on the CAC Score. Hence, there was a zero CAC score group, 
and among patients with positive CAC score, a low CAC score group (1-1000) 
and a high CAC score group (>1000). 
 
Patients with zero CAC Score 
In this patient group, the ability of CCTA to exclude perfusion defects 
was excellent (97% specificity, 90% NPV at the patient level and 99% 
specificity, 97% NPV at the vessel level). 
Sensitivity and PPV in this group could not be estimated due to the 
very small number of patients with demonstrated perfusion defects 
(true positives). In this group, CCTA performed after CAC score did 
not lead to reclassification of any participants. Thus it could be argued 
that CCTA could be avoided in patients with zero CAC score. An 
approach in favour of CAC score used as a gate-keeper prior to CCTA 
was supported by the recently updated 2010 NICE guidance (303) on 
the investigation of stable chest pain of recent onset. According to this 
document, no further testing was recommended in patients with zero 
CAC score. Although it has been shown that non-calcified atheroma 
could be responsible of coronary stenosis in up to 3-4% of cases 
(222), the patients included in this study were free from ischaemic 
symptoms and received a cardiac investigation in the setting of 
screening for coronary artery disease prior to kidney transplantation. 
The finding of zero CAC score excluded both endothelial calcifications 
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from atherosclerosis and medial calcifications from uraemic vascular 
disease. These findings appear quite reassuring in this context, and 
may practically obviate the need of further testing. This particularly 
applies to patients with CKD and ESRD, where the injection of 
iodinated contrast agent may be associated with higher risk of 
nephrotoxicity compared patients withour CKD. 
 
 
Patients with positive CAC score 
The diagnostic performance of CCTA in predicting MPS perfusion 
defects was moderate in patients with a positive CAC score. 
 
The effect of coronary calcification in influencing the diagnostic 
performance of the CCTA is a well known phenomenon (301). 
Coronary calcifications cause partial volume averaging artefacts that 
translate in the visual “blooming effect”. This means calcifications 
appear larger than their actual size on the CT image, and by doing so 
prevent the accurate evaluation of the vessel lumen for the presence 
of luminal stenosis. As a consequence of this phenomenon, the 
coronary arteries may not be accurately evaluable for the presence of 
stenosis, or there can be a tendency to overestimate the severity of 
luminal stenosis leading to false positive diagnoses. This is typically 
reflected by a low PPV. Conversely, CCTA is more robust in ruling out 
coronary stenosis, typically reflected by better NPV. 
 
In patients with high CAC score, defined by an threshold of 1000 
Agatston score (304), CCTA showed very poor agreement (53%) 
compared to the reference standard MPS. Whilst the NPV to exclude 
disease was moderate, the positive predictive value was exceedingly 
low (40%). 
 
However, in patients with low CAC score (between 1 and 1000), the 
agreement between CCTA and MPS was better (84%) and the PPV 
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improved (75%). In this subgroup, the observed prevalence of MPS 
perfusion defects was still low (27%) justifying the use of non-
invasive CCTA as opposed to direct referral to invasive coronary 
angiography. CCTA may be useful to rule-out CAD, given the low 
prevalence encountered in this population and given its robust NPV. 
This is not dissimilar to what has been previously observed in 
symptomatic patients with stable chest pain and no CKD (305). 
However, the ability of CCTA to rule in CAD, when the test outcome is 
positive, may be significantly lower. 
 
In the patients who had unobstructed coronary arteries on CCTA and 
perfusion defects on MPS, CCTA identified LVH, which was confirmed 
echocardiographically in all cases, as a potential explanation for the 
underlying perfusion defects. Myocardial and LVH evaluation using 
the CCTA dataset may provide additional value for the risk assessment 
of patients with advanced kidney disease and uraemia (302).  
 
CCTA is not free from limitations. CCTA requires an intravenous injection of 
iodinated contrast agent, although a small volume (50-60ml, or even less 
with state-of-art technology) may suffice. This can represent a serious issue 
in pre-dialysis patients with severely impaired kidney function, and in 
dialysis patients as well, as residual renal function can be affected. Although 
this did not occur in our study, CCTA can be inconclusive in patients with fast 
and irregular heart rates. CCTA involves the exposure to ionising radiation. 
With latest generation scanners, however, the effective dose is roughly 
comparable or lower than the annual background exposure from natural 
sources, and can be significantly lower than that associated with MPS. Also, 
CCTA can exclude coronary stenosis, but cannot accurately assign ischaemic 
or haemodynamic significance to coronary stenoses, especially of 
intermediate severity (e.g. 50-70% diameter reduction). In these cases, 
testing for inducible ischaemia may still be required. Our study was designed 
as part of a clinical development programme and we did not plan the 
systematic use of invasive coronary angiography, which remains the 
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standard for the evaluation of coronary artery disease, in our study 
participants. Coronary angiography was performed in patients with positive 
findings on non-invasive testing and where clinically indicated. Given our 
population had no ischaemic symptoms (screening settings), a low expected 
prevalence of coronary artery disease and a major comorbidity such as ESRD, 
use of systematic invasive angiography for research purposes would have 
been difficult to justify. This mainly relates to the increased risks secondary 
to the intraarterial injection of iodinated contrast, which is required for 
invasive coronary angiography. Iodinated contrast when injected in the 
arterial circulation may increase the risk of contrast induced nephropathy 
compared to an intravenous injection such as that used for CCTA (306). The 
comparison of CCTA (ie. an anatomical test for CAD) with MPS (ie. a 
functional test for ischaemia) represents a limitation of this study. In view of 
the above mentioned constraints on the use of invasive coronary 
angiography, however, MPS remains the most established and widely used 
reference test used for the cardiovascular screening of kidney transplant 





Chapter 9: Summary of the Thesis and Future Perspectives 
 
9.1 Summary of the Thesis and future work. 
The aim of this work was to compare a novel screening approach based on 
CT, ie. CAC score and CCTA with MPS in the diagnosis of CAD in patients with 
ESRD. We evaluated the diagnostic performance of this approach using MPS 
as the standard of reference. 
We chose CT because it is an established imaging test with proven reliability 
in the evaluation of patients with chest pain from suspected CAD. In this 
thesis, we applied cardiac CT in a population of asymptomatic ESRD patients 
to screen for CAD during routine pre-transplant assessment. 
MPS is the traditionally used test as it is widely available, well established 
and it is based on the assessment of ischaemic changes in the myocardium 
during dynamic exercise or more commonly during pharmacologic stress. 
We found that CAC scoring and CCTA were feasible and of potential clinical 
utility in the setting of cardiovascular risk assessment in ESRD patients. 
The role of CAC score in risk stratification and its prognostic value are well 
known, hence this test has been used for cardiovascular risk assessment in 
the general population (Refer to section 3.3). 
Our data, as well as a previously published study (174), have shown that a 
third of ESRD patients have zero CAC score, which makes the chance of 
having significant coronary artery stenosis very unlikely. Zero CAC score is 
associated with a significant lower rate of cardiovascular events in the ESRD 
population (113). Our results and other studies suggested that CAC score can 
be considered a diagnostic option in the asymptomatic ESRD population 
where further testing can be avoided if the test shows no calcium in the 
coronary arteries (169, 174). 
In patients with calcifications, CCTA could be helpful unless calcifications 
were so bulky to prevent the evaluability of the vessels. In both general 
population (refer to section 4.2.1) and in ESRD patients (252-254) CCTA has 
an excellent NPV (virtually 100%) in the exclusion of CAD. Our study showed 
that in approximately 59% of patients (Figure 9) CCTA was helpful to rule 
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out disease. In patients with severe calcifications, CCTA has lower ability to 
discriminate between patients with CAD vs. without CAD, suggesting that 
CCTA is not a valid replacement to MPS in these situations. 
 
In summary (Figure 8), we suggest that a negative CAC score can identify 
patients who do not need further imaging. Given a positive CAC score, CCTA 
can be performed instead of MPS but only for CAC score <1000. Given the 
high NPV of CCTA in excluding MPS perfusion defects in this group we 
believe that there is no need for further imaging if a patient has a negative 
CCTA (<50% diameter reduction). 
If the baseline CAC score is > 1000, patients still need a functional test, as 
CCTA is not able to predict MPS perfusion defects. Nevertheless, even in this 
group, the identification of very high CAC can be considered important 
additional information to plan patient management. 
 
 
Figure 8. Imaging Approach based on CAC score results. 
 
This novel approach has several benefits for patients: 
If no coronary calcium is found then there is no need for the administration 
of any intravenous contrast, the acquisition time is very short (<5 minutes) 
and more importantly an extremely low radiation dose (effective radiation 
dose below 0.5 mSv in our study) is used. If CCTA is performed (positive CAC 
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score but <1000), an injection of intravenous iodinated contrast is required. 
We have used a low contrast protocol in order to minimise the risk of CIN 
and volume overload in this group of patients. As discussed previously (refer 
to section 4.5), we performed CCTA as close as possible to the next dialysis 
session (the day before or the same day) and no adverse events were 
recorded after CCTA.  
The strength of CCTA+CAC score is to rule out significant epicardial coronary 
stenosis but micro-vascular disease cannot be excluded. An MPS perfusion 
defect may also be uraemia-related micro-vascular disease. In clinical 
practice there is no invasive procedure to treat micro-vascular disease, but 
only medical treatment and correction of risk factors. Knowing that there is 
no significant stenosis in the major epicardial coronary arteries may avoid 
unnecessary coronary angiography even in cases in which there are MPS 
perfusion defects related to micro-vascular disease and/or uraemic changes. 
This novel approach, if used in clinical practice, can be beneficial for a good 
percentage of patients (Figure 9): 
• In 30% of the patients a negative CAC score excludes MPS perfusion 
defects. 
• In 59% of the patients with a positive CAC score, CCTA can still 
exclude MPS perfusion defects. 





Figure 9. Advantages of this novel approach. 
 
Normally, as routine cardiovascular assessment, transplant candidates 
also undergo ECG and echocardiography. Given the excellent agreement 
between echocardiography and CCTA in the detection of LVH, CCTA can 
be regarded as capable of identifying major myocardial and valvular 
structural abnormalities. Using a dedicated, retrospectively ECG-gated 
protocol, CCTA can also evaluate the LV ejection fraction.  
 
Future work: 
- Bone metabolic changes and coronary calcification:  We would 
like to further investigate the relationship between CAC score, 
bone metabolites in the serum and bone mineral density detected 
by CT . 
- Follow-up: a 5-year clinical follow up is planned, which was 
beyond the life span of this PhD project. 
- Further imaging studies with larger populations are necessary to 
investigate further the usefulness and accuracy of CCTA in this 
population. 
- Novel imaging techniques such as native T1 mapping in CMR and 
pseudo-equilibrium CT could be applied to evaluate the extra-
cellular volume fraction in patients with ESRD as a substrate of 
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uraemic cardiomyopathy. These novel imaging biomarkers may 
be prognostically relevant and even help optimise the timing of 
the transplant.  
 
9.2 Future perspectives and hybrid imaging 
CT technology is evolving from a merely anatomical test to a more complete, 
anatomo-functional test. A functional test would complement the anatomical 
information on coronary artery stenosis with functional information on 
either lesion-specific ischaemia secondary to CAD stenosis, or ischaemic 
changes present downstream in the myocardium due to tissue changes or 
remodelling. Several approaches have been proposed to do extrapolate 
functional information on iscahemia based on CCTA: 
Transluminal attenuation gradient (TAG) is the contrast opacification 
gradient through the coronary artery on CCTA. This technique is based on the 
concept of the fall off of the contrast opacification in the distal coronary 
artery beyond the significant stenosis and this could potentially be used to 
better classify lesions(307). At present results regarding TAG are conflicting 
and this new technique has not yet been validated for clinical use (307-310). 
Plaque characteristics can also provide additional important information 
when combined to plaque stenosis. It has been shown that the presence of 
low-density plaque component is indicative of necrotic plaque core which is 
associated with local inflammation and endothelial dysfunction(311). This 
results in local vasoconstriction and inadequate response to vasodilatation 
despite the grade of stenosis, with inability of the vessel segment to dilate 
adequately during stress (311). Given that plaques with necrotic cores are 
the main cause of myocardial infarction and sudden cardiovascular death 
(312) the possibility to identify them can be extremely useful in the 
management of patients. Dedicated software can provide plaque analysis 
identifying calcified, non calcified plaques and also low-density non calcified 
plaques and can be an additional help to discriminate ischaemia compared 
with stenosis evaluation alone (313). 
FFR-CT is a parameter computationally derived from CCTA by applying a 
model representing the resistance to flow during simulated hypaeremia in 
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each coronary branch. A FFR-CT ≤0.80 is considered to be diagnostic of 
lesion-specific ischaemia. Several studies have been published suggesting 
that the diagnostic accuracy of FFR-CT may be superior and additive to CCTA 
alone in identifying ischaemia-causing lesions and reducing the rates of false 
positive lesions incorrectly classified by stenosis alone (314, 315). In the NXT 
trial (316) more sophisticated and new software packages were used and the 
specificity of FFR-CT was found to be markedly better than in previous 
studies. The recent multicenter PLATFORM trial (317) compared the effect of 
FFR-CT-guided testing versus standard diagnostic evaluation on clinical 
outcomes, resource utilisation, costs, and quality of life in patients suspected 
of CAD. The authors found that the strategy of using CT angiography with 
FFR-CT to evaluate patients with suspected CAD was associated with lower 
costs than a strategy based on invasive coronary angiography and it was also 
associated with a better quality of life when compared to other non-invasive 
tests. The main limitation of this technique was the need to transfer CT data 
for external processing and analysis but recent innovation and the use of new 
software can now allow the on-site analysis at a regular imaging workstation 
(318). 
Myocardial perfusion imaging (MPI) using computed tomography has 
become available recently. The detection of myocardial perfusion defects 
with CT is based on imaging the myocardium post contrast injection during 
the phase of peak myocardial enhancement, during infusion of a  
pharmacological stressor, to demonstrate a mismatch between the 
myocardial blood supply and demand. The main advantage of this is the 
possibility of evaluating the coronary artery anatomy and pathology and at 
the same time test the functional significance of a potential coronary stenosis 
(319). This technique can be particularly useful in the intermediate coronary 
lesions (30-70% diameter reduction) where it is difficult to predict ischaemia 
with the anatomical data only (320). Disadvantages are represented by the 






The main advantage of hybrid imaging is to provide in one dataset of images, 
anatomical information provided by CCTA and functional information 
provided by nuclear medicine and in this way by using both datasets, there is 
a reduction in equivocal results (321). 
Hybrid anatomical and functional imaging can help identify the 
emodinamically significant stenosis by providing information about 
myocardial territories and their subtending coronary arteries (322, 323). 
 
It has been reported that 201Tl SPECT/64-row MDCT has a better diagnostic 
performance than CCTA alone in detection 50% stenosis using ICA as 
standard of reference (324).  In particular, the authors found that the hybrid 
technique not only has the high sensitivity and NPV of CCTA but shows a 
significant increase in specificity (from 80 to 92%) and PPV (from 69 to 85%) 
when compared to CCTA alone (324). 
 
Kajander et al. (325) compared PET/CT with invasive coronary angiography 
in patients with stable chest pain with moderate pre-test likelihood of CAD. 
Even though both tests were excellent in the exclusion of significant CAD, the 
hybrid PET/CT imaging was more accurate that both techniques when used 
alone. 
The data available so far indicate that hybrid imaging offers incremental 
diagnostic value in patients at intermediate risk for CAD by improving not 
only the identification of the culprit vessel but it also helps to categorize 
correctly the intermediate lesions and equivocal perfusion defects(326).   
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